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3Farmakogenetikk og morfin i smertebehandling for kreftpasienter 
I den industrialiserte delen av verden øker antall personer som får kreft årlig, 
hovedsakelig på grunn av økt levealder. En av tre nordmenn vil i løpet av sin levetid 
utvikle kreft. Smertebehandling kan være nødvendig ved alle stadier av en 
kreftsykdom, og er viktig for å sikre pasienten best mulig livskvalitet. Morfin anbefales 
som førstevalg av opioider for behandling av moderate til sterke kreftsmerter. 
Imidlertid vil 10 -30 % av pasientene ikke oppnå tilfredsstillende effekt av morfin, 
enten på grunn av uholdbare bivirkninger eller fortsatt smerte – eller en kombinasjon av 
begge. I de tilfeller hvor morfin virker godt, er det dessuten stor variasjon i dosen 
morfin som trengs for å oppnå analgetisk effekt. En årsak til slik interindividuell 
variasjon kan være variasjon i genene. Hvor mange gener som er involvert, og hvilke 
variasjoner det dreier seg om, er ikke klarlagt.   
Ved farmakogenetiske studier finner man ut hvordan variasjon i gener kan påvirke 
effekt og eventuelle bivirkninger av medikamenter. I denne doktorgraden har vi forsøkt 
å finne ut om det er noen gener som påvirker morfinresponsen i en populasjon av 
kreftpasienter med smerter. Vi har sett på to systemer: μ-opioid reseptor systemet og 
catechol-O-metyltransferase systemet. Morfin og andre klinisk viktige opioider bindes 
primært til μ-opioid reseptoren. Derfor er genet som koder for μ-opioid reseptoren 
(OPRM1 genet) viktig. Catecholaminer er involvert i modelleringen av smerte og er 
delvis metabolisert av enzymet, catecholamin-O-metyltransferase (COMT). Det er 
dokumentert at variasjon i COMT genet kan påvirke smertesensitivitet. Hypotesen vår 
er at både OPRM1 genet og COMT genet kan påvirke responsen til morfin hos 
kreftpasienter med smerte.     
Våre funn indikerer at genetisk variasjon i OPRM1 genet og i COMT genet påvirker 
den analgetiske effekten av morfin hos kreftpasienter med smerte. Våre data indikerer 
også at det er interaksjoner mellom to genetiske varianter av OPRM1 og COMT
genene, men populasjonen som er studert er for liten til å si noe sikkert om effekten 
disse to variasjonene har på hverandre. Fenotypen ”morfinrespons i behandling av 
4kreftsmerter” er kompleks, og har uten tvil et sammensatt bidrag fra flere genetiske 
faktorer. Det er sannsynlig at flere gener påvirker fenotypen, og vi er kun i startfasen av 
en reise mot å forstå den komplekse biologien som ligger bak individers respons til 
opioider.
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5“All the big questions are about relationships!”
From the cartoon guide to statistics by Larry Gonick & Woollcott Smith 
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7Summary
The number of cancer patients in the world is increasing mainly because of ageing 
populations. In developed countries it is estimated that about one in three will get 
cancer during their lifetime. In addition to anticancer treatment, pain treatment at all 
stages of the cancer disease is of high priority and an ongoing challenge in clinical 
practice. Whilst oral morphine has been the first line drug of choice for moderate to 
severe cancer pain, 10-30 % of patients treated with morphine do not have successful 
outcomes, either because of intolerable adverse effects or inadequate analgesia - or a 
combination of both. Another issue of morphine treatment is that in cases where it does 
prove efficient, the dose needed to relieve pain varies widely between patients. One 
explanation of the interindividual variation in response to morphine may lie within the 
genes. How many genes are involved, and which variation within well studied genes 
and yet unknown genes, however, is still an unraveled puzzle.
Pharmacogenetics is the studies of how genetic variability influences the responses to 
drugs. In this thesis, using a pharmacogenetic approach, we have investigated the gene-
opioid interaction in patients receiving oral morphine for cancer pain. The genetic focus 
in this thesis has been on two systems, the μ-opioid receptor system and the catechol-
O-methyltransferase system. The μ-opioid receptor is the major site for activation of 
most clinically important opioids, including morphine. Therefore, the gene encoding 
the μ-opioid receptor (the OPRM1 gene) was selected for investigation. 
Catecholamines are involved in the modulation of pain and are partly metabolized by 
the catechol-O-methyltransferase (COMT) enzyme. Variation within the COMT gene is 
believed to influence pain sensitivity and therefore we hypothesized that the COMT
gene is a contributor that influences the response of morphine in cancer pain treatment.   
Our findings indicate that genetic variation in the OPRM1 and the COMT genes are 
influencing the analgesic effect of morphine for patients experiencing cancer pain. Our 
data also indicate that two genetic variants of the OPRM1 and COMT genes display 
joint effects, but larger cohorts are needed to investigate whether these effects are 
8enhancing the efficacy of morphine. The phenotype “morphine response in cancer pain 
treatment” is a multiplex phenotype that has a complex genetic basis. Most likely more 
than two genes influence the phenotype. We are only at the beginning of the journey 
towards a better understanding of the complex biology of opioid response.       
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1. Introduction 
1.1 Translational research 
To improve human health, scientific discoveries must be translated into practical 
applications in the clinic. Such discoveries may begin at “the bench” with basic 
research where scientists study disease at a molecular or cellular level, then progress to 
the clinical level - to the patient's “bedside.” Translational research refers to translating 
research into practice, ensuring that new treatments and research knowledge actually 
reach the patients for whom they are intended (Woolf 2008). This thesis has been a part 
of a translation research project with clinicians, genetists, pharmacologists, 
psychologists, and statisticians working closely together and sharing a main aim of 
research: Improving the scientific basis for individual pain therapy. A brief introduction 
to the translational scientific field is given in the chapters below.
1.1.1 Cancer patients and palliative care  
Every year about 25,000 Norwegians will be diagnosed with cancer and about a third of 
the population will get a cancer disease during their lifetime. The four most common 
forms of cancer are prostate, breast, colon and lung cancer, and the number of new 
cases has been increasing every year since reporting began in 1953 (Cancer Registry of 
Norway 2008). These statistics reflect a real increase in the risk of developing cancer 
disease, but other elements contribute to the increase, such as improved ability to 
diagnose, and an ageing population. About 80 % of new cancer cases are persons aged 
over 55 (Cancer Registry of Norway 2008). Growing old is in itself a risk factor for 
cancer development, due to various risk factors such as environmental influence, gene 
susceptibility and/or random biological mistakes during DNA replication. In Norway, 
survival from cancer disease has slightly increased over the last years, with five-year 
relative survival probabilities of 57% for male and 63% for female cancer patients 
(Cancer Registry of Norway 2007).
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Patients with incurable disease may eventually require palliative care, a medical 
speciality defined by the World Health Organization in 2002 as: 
“Palliative care is an approach that improves the quality of life of patients and their 
families facing the problems associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual” (Sepulveda, Marlin et al. 2002) 
However, palliative care is not medicine exclusively for the terminal patient; patients 
with ongoing anticancer treatment may also benefit from palliative care. Most patients 
are in need of symptom control also when the cancer disease is the main treatment 
target (Kaasa 2007).
1.1.2 Pain 
Pain, is what the patient says hurts, and defined by the International Association for the 
Study of Pain (IASP) as:
“An unpleasant sensory and emotional experience associated with actual or defined 
potential tissue damage, or described in terms of such damage”.
For cancer patients, pain is the symptom which is most feared, and affects most aspects 
of a patient’s life, such as physical functioning, daily activity, psychological and 
emotional status and social life. Eighty percent of patients with advanced cancer disease 
experience pain, and effective treatment of cancer pain is a high priority and ongoing 
challenge in clinical practice (McGuire 2004).
Pain can be classified according to its origin, duration or association with a condition. 
The three main broad categories of pain mechanism are nociceptive, neuropathic and 
idiopathic. Cancer patients are heterozygous in how pain is experienced and how it 
appears (Portenoy and Lesage 1999). The existing approaches to pain classification in 
palliative care are different, mostly not thoroughly validated, and none are widely 
applied (Knudsen, Aass et al. 2009). The reasons for the lack of systematic and 
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widespread use of identified classification systems, may be the complexity of pain and 
the lack of initiatives to reach an international consensus (Kaasa 2007). 
1.1.3 Morphine to treat cancer pain 
Cancer patients may need pain relief at all stages of the disease. Pain may be the first 
symptom of a cancer disease and one of the most prevalent symptoms in patients with 
metastatic disease. The overall aim of pain treatment is to relieve pain to the patient’s 
satisfaction, so that he or she can function effectively and eventually die free of pain 
(World Health Organization 1996). The three-step-analgesic ladder recommended by 
the World Health Organization is the current customary practice for management of 
cancer pain, where opioids remain the drugs of choice for moderate to severe cancer 
pain (World Health Organization 1996). Oral morphine has been the first-line drug of 
choice mainly because there is no ceiling effect or upper limit of doses, and it is a 
naturally occurring pure μ-opioid agonist.
1.1.4 Interindividual variation in morphine responses 
The morphine dose needed to relieve pain varies widely between patients (Hanks and 
Reid 2005). Patients with identical cancer diagnosis, who report pain of equal 
magnitude, may require considerably different doses of morphine. The reasons for these 
interindividual differences are many. Psychological factors such as fear of pain or fear 
of drug effect (Ersek, Kraybill et al. 1999), depression (Laird, Boyd et al. 2008) and 
cognitive function are some examples of factors that may influence pain sensitivity and 
thus also influence the wish for morphine. Cancer patients are often treated with several 
drugs for a variety of symptoms, and drug interactions may contribute to the 
interindividual variation in morphine dose. Several drugs are reported to have a 
potential to interact with morphine, mostly suggested to enhance analgesia and give a 
synergetic effect of morphine (Santillan, Hurle et al. 1998; Wiesenfeld-Hallin 1998; 
Ross, Wallis et al. 2000), but a drug may also reduce the effect of another drug and 
bring about a need for higher doses to reach an ideal effect of treatment (Bernard and 
Bruera 2000).
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The fact that genetic variation contributes to variability in drug responses is widely 
accepted and validated in many research settings (Roden, Altman et al. 2006), so one 
explanation to the interindividual variation in morphine responses may lie within the 
genes.
1.1.5 The big step forward in genetic research 
From about the 1970s, genetic research was a question of hypothesizing whether 
selected genes and variation within genes could interact with diseases or other traits, 
such as drug response. This candidate gene approach led to diagnosis and treatment of 
patients with rare single gene disorders, such as cystic fibrosis (Kerem, Rommens et al. 
1989) and Huntington disease (MacDonald, Ambrose et al. 1993). With the completion 
of the sequencing of the human genome (Lander, Linton et al. 2001; Venter, Adams et 
al. 2001), the establishment of genetic variation databases and the concurrent 
development of powerful techniques, it is now possible to obtain genetic information at 
rates and volumes never done before. The development of genetic medicine has been 
said to gradually change from genetics to genomics (Figure 1).  
Figure 1: The development of genetic medicine illustrating the shift from genetics to genomics 
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By definition genetics is the study of single genes and their effects on the body, while 
genomics is the study of the functions and interactions of all the genes in the genome 
(Guttmacher and Collins 2002). Genetics will soon (if not already) be out of date, 
whereas the genomic era has emerged with tremendous speed along with better, faster 
and cheaper technology. In the genomic era, the focus is to identify genetic contributors 
to multifactorial diseases and common disorders, that is, diseases resulting from the 
combined effect of many genes as well as environmental risk factors. These common 
disorders include, among others, diabetes, cancer, and cardiovascular diseases. The 
molecular genetic methods for analyses search through the majority of known and 
validated genes, and variation within these genes. The enormous volume of genetic 
information obtained with the genomic wide approach has brought about the need for 
new statistical methods of testing for associations.
This thesis was planned, designed, and conducted at the time when the big step forward 
in the field of genetic research was taken. The study design was a candidate gene 
approach and hypothesis testing.
1.2 The pharmacology of opioids 
Pharmacology is the study of the interactions that occur between a living organism and 
exogenous chemicals that alter normal biochemical function. When a drug is given to a 
patient, it is absorbed and distributed to its site of action, where it will interact with 
target molecules, undergo metabolism and finally be excreted. Scientists today believe 
that every pathway of drug metabolism, drug transport and drug effect at receptor level 
will eventually be found to have a genetic variation (Weinshilboum 2003). However, 
patient characteristics such as body fat and water stores, age and muscle wasting may 
also influence the effect of administrated drugs by modifying the amount of opioid in 
plasma (Paice 2007).  
Pharmacokinetics is the study of absorption, distribution, metabolism, and elimination 
of drugs. The term opioid is defined as a compound, both natural and synthetic, that 
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have morphine-like actions. The commonly used opioids in pain treatment, including 
morphine, hydromorphone, oxycodon, fentanyl, and methadone, all differ in their 
pharmacokinetic properties. They also have quite different chemical structures. 
Morphine as compared to alternative opioids is cheap, established (well known), safe 
and has many administrative routes, including oral, subcutanous, rectal, and 
intravenous. In addition, oral morphine treatment for moderate to severe cancer pain is 
recommended by the World Health Organization and the European Association for 
Palliative Care (World Health Organization 1996; Hanks, Conno et al. 2001).
1.2.1 The pharmacokinetics of morphine 
Morphine is a naturally occurring alkaloid 
present in the poppy plant Papaver 
somniferum, also called the opium poppy. The 
morphine molecule consists of five condensed 
rings: phenolic, cyclohexan, cyclohexenol, N-
methyl-piperidine and a partially saturated 
furan ring (Figure 2).  
Figure 2: The morphine molecule 
Oral morphine is extensively absorbed from the intestines (Milne, Nation et al. 1996). 
The predominant metabolic fate of morphine is glucuronidation in the liver, where the 
uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7) enzyme is the catalyst for 
the biotransformation. The two major metabolites from morphine metabolism are 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), although there 
are several other metabolites such as normorphine, normorphine-6-glucuronide, 
morphine-3-sulfate and morphine-3,6-diglucuronide. However, these substances are 
found in small concentrations compared to M3G and M6G (Milne, Nation et al. 1996). 
Of the administrated dose, 55-65% is glucuronidated to M3G, 10-15% to M6G, 5% to 
other metabolites and 10% is excreted unchanged (Osborne, Joel et al. 1990). M3G and 
M6G are consistently found in higher serum concentration than morphine during 
chronic morphine therapy. M6G serum concentration is about six times higher than the 
serum concentration of morphine and the serum concentration of M3G is even higher 
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with a factor of about six times the M6G serum concentration (Klepstad, Kaasa et al. 
2000). There is large interindividual variability in serum concentration. However, while 
the M3G/morphine and the M6G/morphine ratios vary widely, the M3G/M6G ratio is 
more stable (Faura, Collins et al. 1998). Several studies have established that M6G is 
pharmacologically active and binds to the μ-opioid receptor in the central nervous 
system producing even more potent analgesic effects than morphine itself (Mercadante 
1999), while research has ambiguous answers (Klepstad 2002) to speculations on 
whether M3G antagonize M6G and morphine induced effects and whether M3G exhibit 
excitatory effects. 
1.2.2 Optimal use of morphine in pain treatment? 
The optimal use of morphine in cancer pain treatment is to achieve adequate analgesia 
without excessive adverse effects. The effective analgesic dose of morphine ranges 
from as little as 5 mg to more than 1000 mg every four hours, and “finding” the 
therapeutic window for each patients can therefore be a challenge (Figure 3) (Kaasa 
2007).
Figure 3: The therapeutic window 
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The fractions of patients receiving oral morphine that do not reach the therapeutic 
window range from 10% to 30%. These are patients with intolerable adverse effects, 
inadequate analgesia, or a combination of both (Cherny, Ripamonti et al. 2001). 
Adverse effects that prevent further dose escalation and thereby limit the degree of 
analgesia achieved, are a significant problem in clinical practice, but can often be 
overcome by switching to an alternative strong opioid.
The different opioids used in pain treatment share an overall mechanism of action by 
preferentially binding to the μ-opioid receptor. A few genetic terms frequently used in 
this thesis will be schematically presented before the mechanism of opioid action is 
described.
1.4 The genetic terms 
1.4.1.Glossary
About the gene: 
Deoxyribonucleic acid (DNA) is a double helix molecule consisting of 4 bases, 
adenine (A), thymine (T), guanine (G) and cytocine (C) which together form the 
molecular basis of genes.
The gene varies widely in length and composition, but within a gene there is always 
one or more exons (the coding sequence of DNA), one or more introns (non-coding 
sequence of DNA), one or more splice sites (the junction between an exon and an 
intron) and one or more promoter regions (regulatory region of the DNA).  
The genome is the collection of all DNA in an organism. The human genome consist 
of approximately 25 000 genes (Venter, Adams et al. 2001) spread across 23 
chromosome pairs. 
Locus is sometimes used interchangeably with gene, but refers to a location on the 
DNA strand.
Allele is defined as the specific variant found on a particular site in the genome. 
Humans always carry two possible allele variants at a locus, one inherited from the 
mother and another inherited from the father. 
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About genetic variation: 
A phenotype is a trait, a sometimes visual but always measureable property of an 
individual, like for instance height, blood pressure, pain, nausea etc. A universal 
principle in genetics is that virtually all traits have a genetic component.  
DNA variations in humans can be microsatellites, short tandem repeats (STRs), single 
nucleotide polymorphisms (SNPs) or insertion or deletion of DNA. 
SNPs have been given much attention, and currently 14 708 752 SNPs are registered at 
the http://www.ncbi.nlm.nih.gov/projects/SNP database, meaning that the human 
genome on average has 1 SNP every 200 basepair (bp). So far, only about 6 million 
SNPs are validated, but the field is changing rapidly and more details about SNPs in the 
human genome are likely to be revealed in the immediate future. SNPs can either have 
bad, good or indifferent outcomes on the phenotypic level depending on their position 
at the DNA strand and/or within the gene.
Copy number variation (CNV) is large scale copy number variations in the DNA of 1 
kb or larger. CNV can be simple in structure, such as tandem duplications, or may 
involve complex gains or losses of homologous sequences at multiple sites in the 
genome (Redon, Ishikawa et al. 2006). CNVs may influence gene dose effects and are 
therefore suggested to be important contributors to phenotypes. 
About classifying genetic groups: 
A genotype is defined as the combination of alleles on two chromosomes. Genotype 
groups will divide into two homozygous groups with two chromosomes of equal DNA 
information, for example AA and GG, and one heterozygous group of individuals carry 
one of each allele of the SNP, i.e. AG. 
A haplotype is defined as the alleles on different loci carried on the same chromosome, 
meaning a typical haplotype will be given as a combination of DNA nucleotides, for 
instance A-T-C-G-G-C-T.  The length of the haplotype can either be defined simply by 
the number of loci analyzed or limited to capture only SNPs that are highly correlated 
to each other. The latter are said to be within haploblocks.
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About two general concepts: 
Linkage disequilibrium (LD) is a concept in human genetics that refers to the 
nonrandom association of alleles at two or more loci (Slatkin 2008). In other words, not 
all SNPs freely segregate within genes in human populations. D’ is the measure of the 
degree of LD between different loci, and values of D’ is on the continuum from -1 to 1. 
If D’= 1 or -1, there is a complete linkage disequilibrium, and a genotype at one locus 
can predict the genotype at a second locus. If D’= 0, there is linkage equilibrium
between loci, meaning that the genotype present at one locus cannot predict the 
genotype at a second locus.
Epistasis is defined as the interaction between genes (Cordell 2002). 
1.5 Pharmacodynamics 
Pharmacodynamics, the mechanism of opioid action, is often referred to as “what a 
drug does to the body”. The mechanism of opioid action is to provide analgesia, but 
also a variety of other physiological effect such as sedation, nausea and vomiting, 
respiratory depression, confusion, catalepsy, euphoria, and constipation. Opioids act 
through binding to one or more opioid receptors.  
Opioid receptors were demonstrated in the brain by binding studies using radiolabeled 
opioid ligands in the early 1970s (Pert and Snyder 1973; Simon, Hiller et al. 1973; 
Terenius 1973). Many receptors were suggested, but as the research field evolved, three 
of the receptors were regarded as major or ”classical” types, P (mu), N (kappa) and G
(delta). These receptors were cloned in the early 1990s, and the amino acid sequences 
of these receptors are about 60% identical to one another. They all share the same 
general structure of an extracellular N-terminal region, seven transmembrane domains 
and an intracellular C-terminal tail structure (Satoh and Minami 1995). Most commonly 
used opioids in pain therapy bind preferentially to the μ-opioid receptor.
1.5.1 The µ-opioid receptor 
The μ-opioid receptor is a G-protein coupled receptor (GPCR). Mu (μ) opioids induce 
analgesia by inhibiting the ascending transmission of nociceptive information and by 
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stimulating a descending inhibitory system (Basbaum and Fields 1984). More 
specifically, when an agonist binds to the receptor, the receptor in turn binds to a G-
protein and the ȕȖ subunit dissociates from the Į G-protein subunit. The free ȕȖ subunit 
then acts as an effector protein for further signalling and activates a number of second 
messenger systems, among others: Inhibition of adenyl-cyclase, influx of potassium, 
and inhibition of calcium channel activity (Connor and Christie 1999). Opioid receptors 
are expressed both at the spinal level (in the dorsal horn) and in multiple regions within 
the brain (Stein 1993), but they are also widely expressed in the periphery (Bidlack 
2000). Naturally occurring endogenous opioid peptides activate opioid receptors when 
the body is prepared for a “fight or flight” situation.  
Genetic variation in the gene that codes for the μ-opioid receptor (OPRM1 gene) may 
influence the pharmacodynamic properties of opioids. 
1.5.2 The OPRM1 gene 
The gene encoding the μ-opioid receptor is termed OPRM1 and is, in humans, located 
on the long arm of chromosome 6 (6q24-q25). One early model of the murine Oprm1
gene suggested that it contained one promoter and four exons (Kaufman, Keith et al. 
1995). At present, the existence of two promoters (Pan 2002) and 19 exons (Doyle, 
Sheng et al. 2007), encompassing approximately 250 kb of chromosome 10 is known in 
mice (Kvam, Baar et al. 2004). Studies on mice have since 1980 indicated the existence 
of subtypes of the receptor (splice variants), which may be generated by alternative 
splicing of exons in the μ-opioid receptor gene (Pasternak and Snyder 1975; Pasternak, 
Childers et al. 1980). The exons (1-19) in mice are known to alternatively spice and 
generate at least 32 splice variants (Doyle, Sheng et al. 2007). Splice variants of the 
human μ-opioid receptor have also been identified (Bare, Mansson et al. 1994; Pan, Xu 
et al. 2005), but at present the functional relevance and expression pattern have mostly 
been investigated in mice and rats. Future research findings on splice variants of the 
human μ-opioid receptor will reveal new information about the gene structure, and new 
exons may be added to the gene model. As the research on splice variants evolves and 
the complexity of the OPRM1 gene hopefully will be unravelled, three important 
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questions can be asked: Do the new exons in the OPRM1 gene model include genetic 
variation that influence opioid efficacy? Secondly, does the expression pattern of splice 
variants of the μ-opioid receptor vary between individuals? And if so, do they possess 
different binding potential to opioids and do they, as a consequence, influence on 
opioid efficiency in pain treatment?   
1.5.3 Nucleotide variation in the OPRM1 gene
Hundreds of SNPs have been identified in the μ-opioid receptor gene (dbSNP Build ID: 
build129, available from http://www.ncbi.nlm.nih.gov/SNP/ ). Especially, the 118A>G 
SNP (rs17181017) has been given much attention because it leads to an amino acid 
shift from asparagine (Asn) to aspartate (Asp) at amino acid position 40 in the protein 
sequence and is prevalent in most populations. In Caucasians the minor allele frequency 
is about 16%, but there are considerable ethnic differences; the 118 A>G SNP is 
significantly less frequent in African-Americans (Hoehe, Kopke et al. 2000). Two other 
polymorphisms, in intron 2, the IVS2+31 G>A and the IVS2+691 G>C are found in 
European-Americans with a frequency of more than 10%, where the IVS2+31 G>A 
polymorphism disrupts one of the (A/T)GGG repeats and therefore may be important 
for mRNA splicing (Sirand-Pugnet, Durosay et al. 1995). Twenty-four OPRM1 SNPs 
have been regarded as candidates for the variability of clinical opioid effects in a 
review by Lotsch and co-workers, either because they produce an amino acid exchange, 
are frequent (>1%) or are proposed to have functional consequences indicated in in
vitro or in human studies (Lotsch and Geisslinger 2005). The review concludes that 
there are clinical evidence indicating that the 118A>G SNP influence opioid therapy, 
while the role for other SNPs in the OPRM1 gene has not yet been shown.
1.5.4 Current literature when the present thesis was planned  
One in vitro study suggested a functional effect of the 118 A>G polymorphism, as the 
G variant of the receptor binds ȕ-endorphin three times more tightly than the A variant 
(Bond, LaForge et al. 1998). However, these results could not be reproduced by another 
group (Befort, Filliol et al. 2001). The affinity of all other μ-opioid receptor ligands 
(including morphine) used experimentally by Bond et al., and Befort et al., were similar 
for both receptor variants (Bond, LaForge et al. 1998; Befort, Filliol et al. 2001). In a 
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study by Lotsch et al., 12 healthy volunteers were given intravenous morphine and 
M6G, and their pupil diameter was assessed as a measure of central opioid effects. 
Individuals homozygous GG for the 118 A>G polymorphism needed significantly 
higher doses of M6G to obtain a 50% reduction of pupil diameter compared to 
homozygous AA individuals (Lotsch, Skarke et al. 2002), but this was not seen for 
morphine. Sequence variability in the OPRM1 gene was identified in the promoter, 
coding regions and in introns (Hoehe, Kopke et al. 2000).
1.6 The catechol-O-methyltransferase (COMT) enzyme
There is evidence to support interaction between dopaminergic and adrenergic 
pathways and opioid signalling pathways in the central nervous system. Animal studies 
have shown that a chronic activation of dopaminergic neurotransmission is followed by 
a reduction in the neuronal content of enkephalin (Steiner and Gerfen 1998), and a 
compensatory up-regulation of μ-opioid receptors is seen in various regions of the brain 
(Chen, Aloyo et al. 1993; Steiner and Gerfen 1998).
1.6.1 The physiological function of the COMT enzyme 
The catecholamines are neurotransmitters such as dopamine, epinephrine and 
norepinephrine, which are partly metabolized by the catechol-O-methyltransferase 
(COMT) enzyme (Axelrod and Tomchick 1958; Guldberg and Marsden 1975). The 
major physiological function of COMT is to eliminate biologically active or toxic 
catechols. In addition to its role in the metabolism of catecholamines, COMT is 
important in the metabolism of several drugs used in the treatment of hypertention, 
asthma and Parkinson’s disease. There exist both a membrane-bound (MB) and a 
soluble (S) cytosolic form of the COMT enzyme, and at least one of the two distinct 
transcripts is found in all human tissues examined (Mannisto and Kaakkola 1999). S-
COMT dominates in peripheral tissues, such as liver, blood and kidneys, however the 
ratio of MB-COMT to S-COMT in the brain is about 70:30 (Tenhunen, Salminen et al. 
1994; Chen, Lipska et al. 2004). MB-COMT has a higher affinity for dopamine and 
norepinephrine than S-COMT (Lotta, Vidgren et al. 1995). Together, these results 
suggest that MB-COMT is well suited to metabolize catecholamines at the 
concentrations found in the brain (Roth 1992).
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Catecholamines have been reported to be involved in the modulation of pain (Ali, Raja 
et al. 2000; Niemi and Breivik 2002; Pertovaara 2006). Therefore, genetic variability in 
the COMT gene is likely to contribute to differences in pain sensitivity and response to 
analgesics.  
1.6.2 The COMT gene 
The COMT gene is located on the long arm of chromosome 22, at gene map locus 
22q11.2. The gene spans approximately 27 kb and contains two promoters, which 
regulate the synthesis of two distinct transcripts. The most distal 5’promoter (P2) 
regulates synthesis of a 1.5 kb transcript encoding the membrane associated form of 
COMT (MB-COMT, 271 amino acids) and the soluble form (S-COMT, 221 amino 
acids). The second promoter (P1) regulates synthesis of the transcript encoding S-
COMT only (Tenhunen, Salminen et al. 1994). The gene contains six exons, of which 
the first two are non-coding. The MB-COMT and S-COMT are initiated from two 
separate ATG translation initiation codons in exon 3, but share the same single 
translation stop codon in exon 6. The coding sequence downstream of the S-ATG start 
codon is identical for both enzyme forms (Tenhunen, Salminen et al. 1994).  
1.6.3 Nucleotide variation in the COMT gene 
Numerous SNPs have been described in the COMT gene, and 22 of the most frequent 
SNPs distributed throughout the gene have been analysed regarding different aspects of 
pain and opioid responses (Andersen and Skorpen 2009). The most studied SNP is the 
rs4680 (also called Val158Met) polymorphism in exon 3 that gives a change from 
valine (Val) to methionine (Met) at position 108 in S-COMT and at position 158 in 
MB-COMT. The Met variant of the enzyme is associated with low activity and reduced 
thermal stability of the COMT protein (Lotta, Vidgren et al. 1995; Lachman, Papolos et 
al. 1996; Weinshilboum 2006). The low COMT activity appears to be caused primarily 
by reduced levels of the enzyme, as demonstrated in transfected cells (Shield, Thomae 
et al. 2004), human liver (Doyle, Goodman et al. 2004; Shield, Thomae et al. 2004) and 
in brain (Chen, Lipska et al. 2004).
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1.6.4 Current literature when the COMT studies were planned 
Two studies addressing COMT as a contributor to analgesic effect were performed in 
this thesis. The first study was based on the knowledge of the rs4680 SNP in COMT 
and pain modulation. Zubieta and co-workers studied 29 healthy volunteers and 
exposed them to an intensity-controlled sustained muscular pain challenge. Their 
hypothesis was that the rs4680 SNP and the low-function Met/Met COMT enzyme 
would be associated with less capacity to activate μ-opioid neurotransmission under 
provocative painful conditions by virtue of a lower neuronal content of enkephalin. The 
authors confirm their hypothesis, and report that individuals with the Met/Met genotype 
had higher sensory and affective ratings of pain and also higher density of μ-opioid 
receptors in various brain regions (Zubieta, Heitzeg et al. 2003). 
Our second paper addressing COMT as a contributor to analgesic effect was based 
upon previous studies investigating other SNPs across the COMT gene and influences 
on pain perception (Diatchenko, Slade et al. 2005) and morphine related side-effects 
(Ross, Riley et al. 2008). Diatchenko and co-workers investigated the relevance of six 
SNPs along the COMT gene, including the rs4680 SNP, and pain sensitivity in 202 
healthy female volunteers (Diatchenko, Slade et al. 2005). The authors identified three 
haplotypes in the COMT gene, which they designated low pain sensitivity (LPS), 
average pain sensitivity (APS) and high pain sensitivity (HPS) haplotypes, based on the 
their strong association with variation in pain sensitivity. This was measured with 
experimental pain challenges through pressure, thermal and ischemic pain (Diatchenko, 
Slade et al. 2005). A study on post-operative pain ratings among 112 European 
American patients showed associations between maximum post-operative pain ratings 
and the rs740603 SNP located in intron 1 in the COMT gene, but no association was 
seen for the other 13 SNPs analysed (including the rs4680 SNP) (Kim, Lee et al. 2006). 
Ross et al., found that the rs740603 SNP in intron 1 and a haplotype defined by SNPs 
in the promoter region and intron 1 were significantly associated with drowsiness and 
confusion or hallucination in a cancer patient cohort treated with morphine (Ross, Riley 
et al. 2008). Ross and co-workers did not see any impact of the rs4680 SNP on central 
side effects, nor did the rs4680 SNP affect morphine requirements among patients. 
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Taken together, these studies indicate that other SNPs than the rs4680 may be 
important to investigate, in order to elucidate the effect from COMT on different 
aspects of pain and analgesic response.
1.7 Pharmacogenetics or pharmacogenomics?
The terms pharmacogenetics and pharmacogenomics tend to be used interchangeably 
with no precise, consensus definition of either. Nebert et al., define the two as follows: 
Pharmacogenetics is the study of the heritable response to pharmaceutical agents; the 
study of gene-drug interactions. While pharmacogenomics is the study of how 
pharmaceutical agents interact with the total expression output of the genome, to 
influence biological pathways and processes. This latter field should help in designing 
new drugs (Nebert, Zhang et al. 2008).
Pharmacogenetic studies over the past years have revealed a number of high-penetrance 
traits of drug response where single genes are recognized as the major explanation for 
high versus low drug-metabolizing enzymes (reviewed in (Nebert and Vesell 2004)). 
For some of these monogenetic disorders, genotyping is essential and used in the clinic 
to prevent known adverse drug reaction. Test for polymorphisms in the thiopurine-S-
methyltransferase (TPMT) gene is done to avoid severe toxicity to azathiopurine, while 
the purpose of testing for gene duplication of the cytochrome P4502D6 (CYP2D6) is to 
detect ultra rapid metabolizers or poor metabolizers of debrisoquine (Weinshilboum 
2003).
The gene-opioid interaction is multifactorial, as the resulting effect of an opioid is due 
to the combined effect of many genes, as well as environmental factors as for instance 
food, other medication, fear of pain or fear of medication, just to name a few. The 
current evidence for genetic variance influencing the response to opioid in pain 
treatment is sparse. A limited number of genes have so far been investigated, and 
studies involve from a few to a couple of hundreds of individuals (Skorpen, Laugsand 
et al. 2008).
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1.7.1 Other genes influencing the efficacy of opioids 
The current evidence of genetic variation in genes that may influence the efficacy of 
opioids in pain treatment has been reviewed in Skorpen and Laugsand (Skorpen, 
Laugsand et al. 2008). A brief introduction to some of these genes, other than the 
OPRM1 and the COMT genes, is given below.
The uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) enzyme is the 
predominant catalyzer in the metabolism of morphine to its metabolites, morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G). A large interindividual 
variation in the morphine to metabolite plasma ratio has been observed in the clinic. 
Genetic variation in the UGT2B7 gene is hypothesized to influence the efficacy of 
metabolism of morphine. However, the current available evidence suggests that genetic 
variation in the UGT2B7 gene does not influence morphine metabolism to a level that is 
clinically relevant for patients receiving pain treatment (Skorpen, Laugsand et al. 
2008).
Interleukins are a group of cytokines (signalling molecules such as hormones and 
neurotransmitters) that have an important role in inflammatory responses and in pain 
modulation. One study suggests that genetic variation in the interleukin-1 receptor 
antagonist (IL-1Ra) gene affects the consumption of morphine in post operative pain 
(Bessler, Shavit et al. 2006).
The melanocortin-1 receptor (MC1R) gene is associated with red hair and fair skin 
phenotype in humans, but the receptor has also been found in neurons of the ventral 
periaqueductal grey in the brain. These regions are of critical relevance to the 
modulation of nociception (Xia, Wikberg et al. 1995), and one study reports that 
genetic variants in the MC1R gene affect pain and μ-opioid analgesia in mice and 
humans (Mogil, Ritchie et al. 2005).  
The cytochrom P450 (CYP) consists of a group of monooxygenase isoenzymes located 
predominantely on the smooth endoplasmatic reticulum membrane in liver hepatocytes 
32
and along the intestinal tract mucosal surface. CYP2D6 accounts for only 2-5% of the 
total of hepatic P450 isoenzyme, but it catalyzes 25 % of the drugs metabolized, many 
of which are used in palliative care such as codein and oxycodon  (Davis and Homsi 
2001). While it is evident that genetic variants in the CYP2D6 gene influences the 
efficacy of the weak opioid codein, reports on the influence of oxycodon, a strong 
opioid increasingly used in palliative care, are sparse and characterized by small studies 
and case reports (Skorpen, Laugsand et al. 2008).
In order to reach their target of action at opioid receptors, an opioid must cross several 
membrane barriers, including the blood-brain barrier. There are many drug transporters 
that theoretically could be involved in the transport of opioids, but the most intensively 
studied so far is the P-glycoprotein. Interindividual variability in P-glycoprotein activity 
is well recognized, and genetic variability in the multidrug resistance gene MDR1,
which encodes the P-glycoprotein, has been reported to be associated with activity 
differences (Marzolini, Paus et al. 2004). Studies addressing the relevance of genetic 
variations in the MDR1 gene are sparse (Skorpen, Laugsand et al. 2008). 
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2. Aims of the study
The overall aim of this thesis was to investigate the gene–opioid interaction in cancer 
patients. The thesis focuses on two systems – the μ-opioid receptor (OPRM1) system 
and the catechol-O-methyltransferase (COMT) system. The following research 
questions are addressed: 
1) Do selected and frequent single polymorphisms (SNPs) in the OPRM1 gene 
influence on the opioid requirement in cancer pain patients?  
2) Does the frequent polymorphism rs4680 (Val158Met) in the COMT gene, 
which has been associated to the human experience of pain, influence the 
opioid requirement in cancer pain patients? 
3) The 118 A>G SNP in the OPRM1 gene and the rs4680 (Val158Met) SNP in 
the COMT gene influence the opioid requirement in cancer pain patients. Do 
gene joint effects of the two SNPs exist? 
4) Do haplotypes of the COMT gene influence the opioid requirement in cancer 
pain patients?    
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3. Material and methods 
3.1 Patient cohort 
The thesis investigates a cohort originally designed for assessing the relationship 
between patients’ characteristics and serum concentration of morphine and metabolites 
(Klepstad, Borchgrevink et al. 2003). The study included 300 patients who were treated 
at the Trondheim University Hospital during the period June 1999 to February 2000. 
The patients were all diagnosed with malignant disease and received morphine 
treatment. The study allowed for patients to be included more than once. In the thesis, 
which investigates genetic variation, we limited our analyses to the first inclusion of 
each patient, leaving 207 patients available for genetic analyses (Figure 4).  
Figure 4: A flowchart of the included patients. Numbers indicate numbers of patients. 
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A subgroup of 99 patients with good pain control was selected for an analysis 
investigating the relationship between genetic variants in the μ-opioid receptor gene 
and efficacy of morphine (Paper I). Patients who reported four or less on the 11-point 
numeric rate Brief Pain Inventory (BPI) scale item number five, measuring average 
pain the last 24 hours, were included as this patient subgroup was considered to be 
adequately treated with morphine.
In the study investigating the relation between a genetic variant of the COMT gene and 
the efficacy of morphine (Paper II), and in the study (Paper III) investigating joint 
effects of genetic variation found to predict morphine dose for pain control in paper I 
and paper II, all 207 patients were included. For the final study, where genetic analysis 
of haplotypes in the COMT gene were performed, 197 patients were included because 
blood for genotyping was no longer available for 10 patients (Paper IV).
Selection criteria for the inclusion of patients are an important issue for any study. The 
larger the patient cohort is, the stronger statistical power of the analyses. On the other 
hand, careful considerations of the inclusion criteria of patients are crucial for the 
validity of the findings. It is of utter importance for genetic association studies that the 
phenotype investigated is properly defined. For all papers presented in this thesis the 
validity and comparability of morphine dose requirements between the different genetic 
subgroups has been of first priority. In spite of the different study designs for the papers 
in this thesis, we believe that the different genetic subgroups presented are comparable. 
This assumption is based on the thorough discussion of possible confounding factors in 
all papers.
3.2 Assessment tools 
Assessment tools for measuring pain, patients’ health related quality of life (HRQOL), 
cognitive function, and performance status were assessed for all papers in the thesis. 
The assessment tools are enclosed in the Appendix. The questionnaires regarding pain 
and patients’ HRQOL were self-reports, whereas cognitive function and performance 
36
status were assessed by the investigators. Methodological considerations of assessment 
tools used for research purposes should be: 
x Validity: Does the instrument measure what it intends to measure? 
x Reliability: Does the instrument produce the same results when repeated on the 
same population? 
x Inter observer reliability: Does the instrument produce the same results when 
repeated by different investigators? 
x Ability to detect changes: Does the instrument detect clinically meaningful 
changes? 
x Translation: Is the instrument formally validated into the appropriate 
language? 
x Data on the responses in the general population: Are the responses of the 
instrument in the general population known?  
Symptoms such as pain and questions with psychometric properties are challenging to 
communicate and measure, and it is difficult to capture the complexity of the biology 
and psychology in standardized questionnaires. Another important issue in palliative 
care research is that the assessment tools should be short and easy to complete, because 
most patients will be significantly physically and mentally reduced during the progress 
of their disease. The development of a validated assessment tool is time-consuming and 
exacting and the need for expert opinions and research of existing tools is constant. 
There are several methods for measuring pain and patients’ HRQOL. We have used 
validated and well recognized assessment tools in this thesis; all of which will be 
described in the following chapters.  
3.2.1 Measuring pain 
Pain can be assessed with numeric rating scale (NRS), coloured analogue scale (CAS), 
verbal rating scale (VRS), or visual analogue scale (VAS). Assessments can either be 
unidimensional tools targeted to measure one dimension of pain, such as intensity and 
quality, or multidimensional tools targeted to measure several dimensions of pain, such 
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as pain intensity in combination with the pain’s interference with functions and 
temporal patterns. In this thesis (all Papers), pain intensity was measured using the item 
“average pain” during the last 24 hours in the Brief Pain Inventory (BPI) questionnaire. 
The BPI questionnaire uses a NRS with 11-point alternatives, where 0 represents “no 
pain” and 10 represents “pain as bad as you can imagine”. The BPI is a 
multidimensional tool and developed for use towards cancer pain patients, validated in 
Norwegian, and recommended by the European Association of Palliative Care for use 
in clinical studies (Daut, Cleeland et al. 1983; Caraceni, Cherny et al. 2002; Klepstad, 
Loge et al. 2002).
3.2.2 Measuring quality of life 
The European Organization for Research and Treatment of Cancer core quality-of-life 
questionnaire (EORTC QLQ-C30) consists of 30 items for patients’ self report of 
function, symptoms and quality of life (Aaronson, Ahmedzai et al. 1993). The 
psychometric properties and validity of the questionnaire are good (Aaronson, 
Ahmedzai et al. 1993) and the test/retest reliability is optimal (Hjermstad, Fossa et al. 
1995). All scales and single items are linearly transformed giving scores from 0 to 100, 
where higher score means higher levels of symptoms. Twenty-four items are clustered 
into multi-item scales: Physical, Role, Cognitive, Emotional, and Social; three 
symptom scales: Fatigue, Pain, and Nausea and vomiting; and a global health and QOL 
scale. Finally, there are six single items covering dyspnoea, sleep, appetite, 
constipation, diarrhoea, and financial impact of the disease and treatment.  
Both questionnaires, the BPI and the EORTC QLQ-C30 were delivered and collected 
directly to and from the patients. This procedure ensured that all questionnaires were 
returned.
3.2.3 Other assessments
Cognitive function was assessed by the Mini Mental State examination (MMSE). The 
MMSE scores range from 0 to 30, with higher scores indicating better cognitive 
function. This is a standardized cognitive screening examination which has proven 
valid, reliable and able to document changes in cognitive function (Folstein, Folstein et 
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al. 1975). The feasibility of MMSE has also been demonstrated in studies on patients 
with terminal cancer (Pereira, Hanson et al. 1997). The patients’ functional status was 
assessed using the Karnofsky performance status score (Karnofsky, Abelmann et al. 
1948).
We are aware of the possible confounding effect on the measurement of pain because 
of patients with low MMSE or Karnofsky scores, and patients who were not able to 
complete the MMSE. Therefore we reported the Karnofsky and MMSE scores across 
genotypes in order to reveal any skewed distribution that could lead to a bias of the 
analyses.
3.3 Pharmacological analyses 
All blood samples for the determination of serum concentrations of morphine, M6G 
and M3G, were obtained during the routine morning round for collection of blood 
samples. The blood samples were placed in tubes, serum separated by centrifugation, 
and finally stored at -85°C. Westerling et al., have compared the effects of different 
preanalytical conditions on the measurement of morphine, M6G and M3G serum 
concentrations, such as different tubes, temperature and time of storage. They found no 
influence on morphine, M6G or M3G serum concentrations (Westerling, Bengtsson et 
al. 1996). Thus, the analyses of morphine, M6G and M3G are robust to different 
handling procedures pre analysis.
In this study, blood samples were not taken at an exact time after morphine 
administration. This approach was used in order to facilitate the feasibility of clinical 
routine drug monitoring of morphine. All patients in the presented cohort were on 
stable doses of morphine, and smaller fluctuation of serum concentration of morphine 
and metabolites are expected during a dose interval compared to studies for effects after 
single opioid administration.    
3.4 Molecular genetics 
Genomic DNA was isolated from 50 to 200 μL EDTA blood on a MagNA Pure LC 
(Roche Diagnostics Scandinavia AB, Bromma, Sweden) using the MagNA Pure LC 
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DNA Isolation Kit I and applying the manufacturers high performance protocol. 
Purified genomic DNA was eluted in 100 μL antiseptic water or elution buffer and 
stored at – 20 ºC. 
3.4.1 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is the gold standard procedure for generating large 
quantities of a specific DNA sequence in vitro, and essential before sequencing or 
genotyping DNA strands of interest. DNA amplification by PCR, which can be more 
than a million fold, is achieved by a three-step cycling process including denaturation at 
95°C, renaturation at about 60°C and synthesis of DNA at about 70°C. These three 
successive steps are repeated a number of times, e.g. 40. The essential requirements for 
the PCR are two synthetic oligonucleotide primers (a 20 nucleotides each) that can 
match and pair to specified regions in the target DNA, the DNA sample from an 
individual, a thermo stable DNA polymerase and the four deoxyribonucleotides, dATP, 
dGTP, dCTP and dTTP (or dUTP).
3.4.2 Genotyping SNPs 
If a SNP is known, frequent and of interest to analyze, genotyping is preferable to DNA 
sequencing because it is cheaper and less time-consuming. In this thesis, two methods 
for genotyping were used, a LightCycler PCR system using the fluorescence resonance 
energy transfer (FRET) method and a sequence specific polymerase chain reaction 
(SSP-PCR) method.  
Genotyping using FRET method 
Genotyping with the FRET method was carried out on the LightCycler system. A target 
DNA which includes the polymorphism of interest is first amplified by PCR. After the 
PCR run, polymorphism detection is carried out in the same reaction capillary. Two 
separate 3' and 5' probes are labeled with donor and acceptor fluorophores, and 
designed to match part of the PCR product, including the polymorphic site. The probes 
are added in the reaction mix, but will not distract the PCR process.
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After the PCR is completed the probes will anneal to its target DNA and an increase in 
FRET is observed because the donor and acceptor fluorophores get into close proximity 
(Figure 5).
Figure 5: The FRET signal. Two probes, designed for polymorphism detection on the LightCycler, match 
the DNA sequence in the region where the polymorphism is located. The polymorphism site is indicated 
by a little orange box in the DNA sequence. The probes are labeled with fluorophores donor (F1) and 
acceptor (F2). When the probes get in close proximity hv (a light source from the LightCycler 
instrument) will excite F1, which again excites F2 resulting in a FRET signal.  
Further on, the reaction tube is heated and the probe/target duplex is denatured. The 
fluorophores get separated and the FRET signal drops to the background. The sensor 
probe is designed to have either of the two possible DNA sequences at the polymorphic 
site. The probe/DNA target duplex will sometimes (depending on the patient's 
genotype) have a mismatch position which decreases the stability of the duplex. This is 
reflected by a shift in melting temperature (Tm) visualized on the LightCycler System. 
As an example, a homozygous AA genotype will generate one Tm peak, a homozygous 
GG genotype will generate one Tm peak and a heterozygous AG genotype will generate 
two Tm peaks. This happens because half of the target DNA will match completely with 
the sensor probe, while the other half will not (Figure 6). 
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Figure 6: A schematic presentation of an imagined genotyping result from the LightCycler, showing the 
three possible genotypes (AA, GG and AG) as colored peaks. 
Genotyping with the FRET method is reliable, accurate and fast. However, low quality 
of the DNA, procedure failure by the investigator and some genomic constructions as 
copy number variation, may cause problems and equivocal results. Genotype results 
were confirmed with DNA sequencing for each of the SNPs analyzed in the present 
thesis.
Genotyping using SSP-PCR method 
The SSP-PCR method is based on the concept that a sequence specific primer and a 
consensus primer produce a DNA product of known size in a PCR run. The sequence 
specific primer has a mismatch at the 3’ end, which is designed to identify each 
genotype variant. Primer concentrations were titrated to ensure amplification only with 
exact matching of the primer with genomic DNA. Products were visualised with a UV 
illuminator and photographed with a Polaroid camera. The presence of an allele specific 
band of the expected size, in conjunction with a control band, was used to identify an 
allele. 
The SSP-PCR method has an overall good resolution and results are easy to interpret. 
As for genotyping using the FRET method, equivocal genotypes usually relate to the 
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quality of the DNA, deviations from standard procedures and/or complexity of the 
human genome.  
3.5 Statistical methods 
The patient data used in this thesis were originally included into a study designed for 
assessing the relationship between patients’ characteristics and serum concentrations of 
morphine and metabolites, therefore a prestudy formal sample size calculation was not 
performed. The Statistical Package for Social Science (SPSS) was used for all analyses 
in all Papers. The statistical methods that were used vary for the different papers, and 
detailed descriptions are outlined in each of the presented papers. A brief description is 
given below.  
3.5.1 Statistical analyses for all papers 
In Paper I, comparisons between different genotype groups for each of the OPRM1 
polymorphisms were performed with one-way ANOVA tests. A p-value less than 0.01 
was considered statistical significant in order to give some protection against multiple 
tests.
In Paper II, comparisons between the different genotypes (Val/Val, Val/Met and 
Met/Met) were then performed with the Jonckheere-Terpstra test, a non-parametric test 
working with the hypothesis that μ1μ2μ3 (or the opposite μ1μ2μ3). The test was 
chosen because the COMT alleles are expected to be codominant with respect to 
enzyme activity. In other words, we expected a gene-dose effect of the rs4680 
polymorphism in respect to the need for morphine. A p-value less than 0.05 was 
considered statistical significant.       
In Paper III, we performed a multivariable logistic regression analysis using morphine 
dose as the dependent variable. Odds ratio with accompanying 95% upper and lower 
bonds are chosen to present results from the logistic regression model of morphine 
dose.
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In Paper IV, we used non-parametric tests for comparisons between genotypes and 
haplotypes against morphine doses and a stepwise linear regression analysis with the 
morphine dose as the dependent variable. The Jonckheere-Terpstra test for comparison 
between genotype groups was used for the rs4680 polymorphism, as explained for 
Paper II. For all other SNPs we used the Kruskal-Wallis test for comparison between 
genotype groups. For the analyses of comparisons between haplotypes and morphine 
doses we used the Mann-Withney U-test. We used the logarithm (log10) of the 24 hour 
morphine dose as the dependent variable in the regression analyses because the 24 hour 
morphine dose, as expected, did not display a normal distribution. The analysis was a 
stepwise enter linear regression with a criterion for removal of a variable of p>0.1. The 
variables included in the regression analysis as independent variables are outlined in 
Paper IV.
3.5.2 Genotype data 
Individual SNPs were examined for genotype and allele frequencies (all papers) and 
allele carriage (Paper IV). The genotype frequency was calculated by simply counting 
the number of individuals in the different genotype groups. The allele frequency is the 
percentage of loci that the allele occupies within the population, and is calculated as 
shown below.
Allele frequency: 
[(2 x #homozygote) + (1 x #heterozygote)] / total #alleles
The allele carriage presents whether an individual carries the allele regardless of being 
homozygous or heterozygous carrier. The allele carriage is calculated as shown below. 
Allele carriage:  
#homozygote + #heterozygote / total #individuals 
The Hardy-Weinberg principle states that both allele and genotype frequencies in a 
population remain constant. Consequently, a random genetic sample has a distribution 
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of homozygous and heterozygous carriers that correspond to the Hardy-Weinberg 
equilibrium. Violation of the Hardy-Weinberg model may be the result of non-random 
mating, limited sample size or a possible genotyping system error. The Hardy-
Weinberg model compares the observed and expected genotype frequencies, and is 
based on two equations: 
1) p+q=1 
2) p2 + 2pq + q2 = 1 
Where p is the frequency of one allele; q is the frequency of the other allele; p2 is the 
frequency of one homozygous group; 2pq is the frequency of heterozygous individuals; 
and q2 the frequency of the other homozygous group.
All genotype frequencies were checked for Hardy-Weinberg equilibrium using the Ȥ2 -
test. Allele frequencies are determined directly from the data available on the 
population investigated, and the expected genotype frequencies are calculated using the 
equation number 2 above. Significant (p<0.05) differences between expected and 
observed genotype frequencies indicate that the study population is not in Hardy-
Weinberg equilibrium.  
3.5.3 Construction of haplotypes (paper IV) 
The series of genotype information on a given stretch of DNA is unphased data, which 
means that we can not tell on which chromosome the series of SNPs lie. Phased data 
can be established by genotyping family members to infer parental chromosomes, or 
estimated by the use of different statistical methods. There are two frequently and 
widely recognized methods for constructing haplotypes; the Expectation-Maximization 
(E-M) algorithm, and the Bayesian method. In the presented thesis, the haplotypes were 
predicted using the Bayesian approach with the computer program Phase 
(http://stephenslab.uchicago.edu/software.html) (Stephens, Smith et al. 2001; Stephens 
and Donnelly 2003). Phase has shown to offer accuracy of estimation and ability to 
incorporate genotyping error and/or missing data (Stephens and Donnelly 2003).
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3.6 Ethics 
The study was carried out in accordance with the principles of the Helsinki declaration. 
The Regional Committee for Medical Research Ethics, Health Region IV, Norway, 
approved the study. All patients gave their oral and written informed consent before 
inclusion in the study. However, a challenge in palliative care research is that a 
majority of the patients are in a vulnerable situation with advanced cancer disease, and 
many of them have therefore reduced ability to give informed consent. In palliative 
research, it is of utter importance to be aware of the difficulties in obtaining adequate 
informed consent, and observe a special obligation to give patients relevant and 
understandable information about the study.  
The findings of the presented genetic association studies may potentially be of benefit 
for future patients, because the specified genetic information can be used to improve 
pain treatment. However, it is possible that not all genetic information is in the patient’s 
best interest, because some genetic variants may predict more than one phenotype. In 
other words, if genetic tests are future tools in medicine they may carry “good news” 
about how to facilitate pain treatment, but the same tests may bring “bad news” about 
possible onset of disease or more likely for instance susceptibility to drug abuse. An 
ethical discussion pre use of future genetic tests in medicine is therefore essential.    
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4. Summary of papers 
Paper I 
The 118 A>G polymorphism in the human µ-opioid receptor gene may increase 
morphine requirements in patients with pain caused by malignant disease. 
Morphine is recommended by the World Health Organization as the treatment of choice 
for moderate to severe cancer pain. Despite its widespread use, the many side effects 
and the large individual differences in doses required have complicated its use in 
clinical practice.  
The μ-opioid receptor is the major site for most clinically important opioid drugs, 
including morphine. The aim of the study was to investigate if selected SNPs in the µ-
opioid receptor (OPRM1) gene influence on the efficacy of morphine in cancer patients 
with pain. The selection of SNPs was based on the frequency of occurrence in 
Caucasian population and current literature.
Two hundred and seven patients were genotyped for the well studied 118 A>G SNP, 
the -172 G>T SNP in the 5’regulatory region, and the IVS2 + 31 A>G and the IVS2 + 
691 G>C SNPs in intron 2, all within the μ-opioid receptor gene. A selection of 99 
patients, with adequately controlled pain, was compared against morphine doses 
between genotype groups for all SNPs. We found no differences of morphine doses 
between genotype groups for the -172 G>T (96±92mg/24h, 108±73mg/24h, 30 
mg/24h); the IVS2 +31 (94±87mg/24h, 111±107mg/24h); and the IVS2 + 691 SNPs 
(99±133mg/24h, 87±68mg/24h, 108±96mg/24h). On the contrary, we found that 
patients homozygous for the G variant of the 118 A>G SNP needed more morphine 
(225±143mg/24h) compared to heterozygous individuals and patients homozygous for 
the A variant of the SNP (97±89mg/24h).  
The 118 A>G SNP affects the structure in the extracellular region of the μ-opioid 
receptor as the substitution from A to G leads to an amino acid shift in the protein from 
asparagine to aspartate. The 118 A>G SNP has been the most extensively studied 
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because it is speculated that it may affect the binding efficacy of substrates to the 
receptor.  
Our data indicate that genetic variation in the OPRM1 gene may influence the efficacy 
of morphine in a cancer patient cohort. The findings need to be validated in a larger 
study sample.  
Paper II 
The Val158Met polymorphism of the human catechol-O-methyltransferase 
(COMT) gene may influence morphine requirements in cancer pain patients. 
Pain and the efficacy of analgesics are traits of complex genetic basis most likely 
influenced by a number of genes. The COMT enzyme metabolises the catecholamines: 
Dopamine, epinephrine and norepinephrine, and is therefore considered a key 
modulator of dopaminergic and adrenergic neurotransmission. A common and well 
studied SNP in the COMT gene is the rs4680 (Val158Met) polymorphism, because it 
has been shown to reduce the COMT enzyme activity three-to-four fold. One study, 
investigating the influence of the rs4680 SNP on pain perception, found that subjects 
with the Met/Met genotype have the most pronounced response to experimental pain 
compared to heterozygous Val/Met and Val/Val genotype individuals.
The aim of this study was to find out whether the rs4680 SNP influence on the 
morphine efficacy for cancer pain. Two hundred and seven patients were genotyped 
and analyzed for differences in morphine dose requirements, serum concentration of 
morphine and morphine metabolites. In the presented Norwegian cohort the Met allele, 
corresponding to the low-activity COMT enzyme, was the most frequent with a relative 
frequency of 0.56. The morphine dose requirements for the Val/Val, the Val/Met, and 
the Met/Met genotype groups were 155±160mg/24h, 117± 100mg/24h, and 
95±99mg/24h respectively. This difference was statistically significant with p=0.025, 
and was not explained by other factors such as duration of morphine treatment, 
performance status, time since diagnosis, perceived pain intensity, adverse symptoms or 
time until death.  
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The findings in this study suggest that the rs4680 SNP in the COMT gene may 
contribute to the efficacy of morphine in a cancer patient cohort. This is of principle 
interest since it demonstrates that genetic variability in genes not directly relevant to 
opioid systems can influence the efficacy of morphine.  
Paper III 
Exploring joint effects of genes and the clinical efficacy of morphine for cancer 
pain: OPRM1 and COMT gene. 
Pain and the efficacy of analgesics are traits of complex genetic basis most likely 
influenced by a number of genes. Two SNPs, the 118 A>G and the rs4680; in two 
genes, the OPRM1 gene and COMT gene respectively, have been suggested to be 
modulators of morphine efficacy. The joint effects of genes can be expected to enhance, 
suppress or have no effect on the phenotypic outcome of interest. The aim of this study 
was to assess the joint effects of these SNPs in the OPRM1 and COMT genes to the 
morphine dose requirements in a cancer patient cohort.
We used the genotype data obtained in Paper I and II and clinical data from the original 
pharmacokinetic study. Two hundred and seven patients were included in a 
multivariable logistic regression analysis using morphine dose as the dependent 
variable. In Paper I and Paper II we reported that the A allele (OPRM1) and the Met 
allele (COMT) were associated with the lowest morphine dose requirements. In this 
study we found that carriers of the combination OPRM1 AA and COMT Met/Met 
genotype, required the lowest morphine doses (87mg/24h; 95%CI=57,116), while 
patients carrying neither AA nor Met/Met genotype needed the highest morphine doses 
(147mg/24h; 95%CI=100,108). The differences of morphine dose requirements seen 
between genotype combinations were significant with a p value of 0.012, even after 
controlling for demographic and clinical variables in the multivariable analysis.   
The findings from this study indicate that there are joint effects from the 118A>G SNP 
and the rs4680 SNP in the OPRM1 and the COMT gene respectively.  Larger cohorts 
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are needed to investigate whether these effects are enhancing the efficacy of morphine 
in cancer pain treatment.  
Paper IV 
Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine 
requirements in cancer patients with pain. 
Genetic variability in the COMT gene is believed to contribute to differences in pain 
perception and response to analgesics. In Paper II we reported that the rs4680 SNP in 
the COMT gene may influence on the efficacy of morphine in cancer pain treatment. 
The aim of this study was to investigate if variability in other regions of the COMT
gene also contributes to the interindividual variability in morphine efficacy. 
Specifically, we wanted to find out whether haplotypes of the COMT gene influence the 
requirement of morphine in a cancer patient cohort.  
Eleven SNPs throughout the COMT gene were genotyped, all of which were in Hardy-
Weinberg equilibrium. The SNPs were located in the promoter region, in intron 1, 2 
and 3, in exon 4, intron 5, and in the untranslated 3’ region. They were selected for 
analyses on the basis of frequency, position within the gene, and what was known from 
relevant literature. Genotypes and haplotypes were compared with pharmacological, 
demographical and patient symptoms measurements in 197 cancer patients receiving 
scheduled oral morphine for cancer pain. Two frequent haplotypes (34.5% and 17.8%) 
were found in this cohort. Using a multivariate regression method with morphine dose 
as the independent variable, we found that patients carrying the most frequent 
haplotype (34.5%) were predicted to need lower morphine doses than patients not 
carrying this haplotype, with a reduction factor of 0.71 (p=0.005). Non-parametric tests 
show that there were weak associations between allele carriages for six of the SNPs 
analysed. The six alleles associated with the lowest morphine doses constitute part of 
the most frequent haplotype. 
The findings in this paper suggest that genetic variability in the COMT gene influence 
the efficacy of morphine in cancer patients.          
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5. Discussion 
The overall aim of this thesis was to investigate the gene-opioid interaction for two 
systems, the μ-opioid receptor and the catechol-O-methyltransferase system. The 
included papers indicate that genetic variation in both systems may influence on the 
efficacy of morphine in cancer pain treatment. The findings are a step forward to a 
better understanding of the complexity of biological factors that contribute to the 
response of opioids in pain treatment. The following chapters will successively discuss 
the implication of findings, recent literature, limitations within the papers presented, 
and general limitation in a pharmacogenetic study design.
5.1 The µ-opioid receptor (Paper I) 
Paper I answers the research question number one. Of the four selected SNPs in the 
OPRM1 gene, only the 118A>G polymorphism in the OPRM1 gene influences on 
morphine requirements in a cancer patient cohort. Patients homozygous for the G allele 
needed more morphine to achieve pain control compared to heterozygous AG and 
homozygous AA individuals. The available evidence that suggests a clinical relevance 
of the G allele of the 118 A>G polymorphism is relatively strong per date. Several 
studies have addressed the functional consequences of this polymorphism in healthy 
volunteers.
5.1.1 Studies in healthy volunteers  
The study by Lotsch and co-workers, where the 118 A>G polymorphism in the OPRM1
gene was found to decrease pupil constrictory effect of M6G (Lotsch, Skarke et al. 
2002), has been followed up in a study using similar methodology (Skarke, Darimont et 
al. 2003). In this follow-up study, the effect of the 118A>G SNP on M6G efficacy was 
confirmed, but they also found that the potency of the pupil-constricting effects of 
morphine was significantly smaller in subjects carrying the G allele. These individuals 
also reported less nausea and vomiting after administration of M6G. However, no effect 
on analgesia was identified in this study, and the importance of the 118 A>G SNP on 
morphine and M6G efficacy is debated. The authors conclude that pain data are 
“noisier” than pupil data, and that the study may be too small (12 individuals) to 
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produce conclusive data (Skarke, Darimont et al. 2003). Two other studies, also 
addressing the effect of the 118A>G SNP and the efficacy of M6G, showed a reduced 
analgesic response to M6G in individuals carrying the G allele (Romberg, Olofsen et al. 
2004; Romberg, Olofsen et al. 2005), but suggest that the 118 A>G SNP does not 
protect against opioid induced respiratory depression (Romberg, Olofsen et al. 2005). 
In sharp contrast to the studies by Romberg et al., Oertel and co-workers report that 
homozygous carriers of the 118 G allele needed 10-12 times higher concentration of 
alfentanil to elicit the same degree of respiratory depression (Oertel, Schmidt et al. 
2006), suggesting that increasing opioid dose in homozygous 118G allele carriers to 
achieve adequate analgesia is clinically safe. The same study showed that higher 
alfentanil concentrations (2-4 times) were needed to produce the same degree of 
analgesia in homozygous carriers of the G allele, compared to homozygous A allele 
carriers of the 118 A>G SNP (Oertel, Schmidt et al. 2006). Finally, Lotsch and co-
workers have reported that pupil constriction, in 51 healthy volunteers receiving 
levomethadone, are associated to the 118 A>G SNP (Lotsch, Skarke et al. 2006).
To summarize, many studies support each others’ findings that there is actually an 
effect of the 118 A>G SNP on opioid efficacy (Lotsch, Skarke et al. 2002; Skarke, 
Darimont et al. 2003; Romberg, Olofsen et al. 2004; Romberg, Olofsen et al. 2005; 
Lotsch, Skarke et al. 2006; Oertel, Schmidt et al. 2006).  
5.1.2 Clinical studies 
Two recent clinical studies support our findings, by reporting a possible relevance of 
the OPRM1 118A>G polymorphism for post-operative opioid consumption. Both 
studies report an increased consumption of intravenous morphine (patient-controlled) in 
patients homozygous GG for the 118 A>G polymorphism, compared to patients 
homozygous AA (Chou, Wang et al. 2006; Chou, Yang et al. 2006). However, these 
studies have been criticized because the 118 A>G SNP was not in Hardy-Weinberg 
equilibrium (Lotsch 2007). Furthermore, the difference reported in morphine 
consumption (33±10 mg versus 27±9 mg (Chou, Wang et al. 2006)) was questioned by 
Ruth Landau, who argued that the difference was too small to be of any clinical 
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relevance, especially since it was only seen the first 24 hours of treatment and 
disappeared after 48 hours (Landau 2006). Another study, involving 145 cancer patients 
undergoing pain treatment, indirectly supports our findings (Campa, Gioia et al. 2008). 
An association between the degree of pain relief and the 118 A>G polymorphism was 
found; the patients being homozygous carriers of the 118 A allele were associated with 
the highest pronounced decrease in pain after 7 days of morphine treatment (Campa, 
Gioia et al. 2008). A recent study investigated the response to morphine for 
postcesarean analgesia in 588 women, and showed that patients being homozygous 
carriers of the 118 G allele in the OPRM1 gene needed the highest doses of morphine to 
relieve pain (Sia, Lim et al. 2008). The study by Sia et al., also clearly supports our 
findings in Paper I. One study investigating the morphine dose requirements in patients 
undergoing colorectal surgery, reports no effect of the 118 A>G polymorphism, neither 
on patient controlled analgesic requirements nor on postoperative nausea or vomiting 
reports (Coulbault, Beaussier et al. 2006). Finally, one study shows the complete 
opposite of the above mentioned studies, reporting that women with the 118 G allele 
may be more responsive to opioids and require less analgesic drugs (Landau, Kern et al. 
2008). The design of this study involved intrathecal fentanyl for laboring women and 
the authors discuss their opposite findings with respect to the effect of the different 
nature of nociceptive stimulus in labor versus that perceived in experimental models, or 
in acute postoperative or chronic settings.
Taken together, the available evidence suggests that the 118 A>G SNP in the OPRM1
gene is associated with reduced opioid effect (as seen for pupil construction, response 
to experimental pain and respiratory depression) and an increased opioid dosage 
requirement in patients. However, there seem to be different effects for the different 
opioid drugs and responses. This is probably due to the complex and numerous 
biological pathways and contribution of environmental factors and other genes 
affecting opioid responses.
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5.1.3 Functional studies addressing the importance of the 118 A>G SNP 
Two likely explanations for the reported effect of the 118 A>G SNP is postulated, both 
hinting that it might affect the binding potential of the receptor. Firstly, the SNP is 
located in the gene in such a way that it affects the extracellular region of the receptor 
were opioids bind. Secondly, the SNP causes an amino acid substitution from 
asparagine (Asp) to asparatate (Asn), consequently deleting a putative N-glucosylation 
site and possibly affecting binding efficacy of different molecules. The important 
question is: Does it influence on opioid binding? The widely cited in vitro study by 
Bond et al., showing that ȕ-endorphin had an increased binding affinity with the Asn 
receptor type (Bond, LaForge et al. 1998), has not been replicated by others (Befort, 
Filliol et al. 2001; Beyer, Koch et al. 2004; Kroslak, Laforge et al. 2007). Thus, 
attempts to identify the molecular mechanisms of the clinically observed effects of the 
118 A>G SNP on analgesic response have been inconsistent. It has been suggested that 
the inconsistence in findings may be attributed to the artificial conditions in non-human 
non-neuronal cells, and also partly to the neglect of region dependent effects of μ 
opioidergic mechanisms in the human brain (Oertel, Kettner et al. 2008). The presence 
of the 118 A>G SNP has been reported to decrease analgesic effects of alfentanil at 
brain regions processing the sensory dimension of pain, but not at brain regions 
processing the affective dimension of pain (Oertel, Preibisch et al. 2008). Oertel and 
co-workers investigated the 118 A>G SNP in regard to μ-opioid receptor signalling, 
expression and binding affinity in human brain tissues, sampled post mortem from two 
regions involved in the sensory processing of nociceptive information. The main effect 
of the 118 A>G SNP was shown to be a reduction of the agonist-induced receptor 
signalling efficacy, and these results were only evident in the secondary somatosensory 
area (S11) of the brain (Oertel, Kettner et al. 2008).   
5.1.4 The frequency of the variant G allele 
Four patients were homozygous GG for the 118A>G SNP in our study. The relatively 
low frequency of occurrence of the SNP brings a limitation to studies with small 
sample sizes. In many of the above mentioned studies the number of homozygous GG 
carriers of the 118 A>G SNP are low, with values varying from zero to 10 in the 
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clinical studies (Chou, Wang et al. 2006; Chou, Yang et al. 2006; Coulbault, Beaussier 
et al. 2006; Campa, Gioia et al. 2008; Landau, Kern et al. 2008) and values varying 
from zero to six in the studies including healthy volunteers (Lotsch, Skarke et al. 2002; 
Skarke, Darimont et al. 2003; Romberg, Olofsen et al. 2005; Lotsch, Skarke et al. 2006; 
Oertel, Schmidt et al. 2006). One exception is the study by Sia et al., where the 
numbers of GG individuals are 82 (Sia, Lim et al. 2008). Future studies should involve 
large sample sizes to elucidate the role of the 118A>G SNP in the OPRM1 gene and 
opioid efficacy.
5.2 The COMT enzyme (Paper II and IV) 
Paper II and IV show that the variability in the COMT gene influences on morphine 
requirements in a cancer patient cohort. Paper II answers the research question number 
two, and suggests that the rs4680 SNP is influencing the efficacy of morphine. Patients 
homozygous Met/Met needed less morphine (95±99 mg/24h) than homozygous 
Val/Val (155±160 mg/24h) patients. Paper IV answers the research question number 
four, and suggests that more of the genetic variability in the COMT gene is influencing 
the efficacy of morphine in cancer patients with pain, by showing that carriers of a 
frequent haplotype defined by 11 SNPs across the entire COMT gene needed lower 
morphine doses than patients not carrying the haplotype. Median morphine doses for 
carriers of this haplotype were 60 mg/24h versus median morphine doses of 100 
mg/24h for non-carriers of the haplotype. The available literature today on variability of 
the COMT gene and different pain phenotypes as well as opioid response is complex, in 
the sense that some studies find association to the well-studied rs4680 SNP (Zubieta, 
Heitzeg et al. 2003; Diatchenko, Nackley et al. 2006), whereas others do not (Kim, 
Neubert et al. 2004; Diatchenko, Nackley et al. 2006; Ross, Riley et al. 2008). Most 
studies have addressed the variability in the COMT gene with different aspects of pain 
sensitivity.
5.2.1 Variability in the COMT gene and pain perception 
The study by Diatchenko et al., (Diatchenko, Slade et al. 2005), showing that 
haplotypes of the COMT gene were strongly associated to sensitivity of pain, has been 
followed up in a study using the same cohort, hypothesizing that different genetic 
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variants of the COMT gene contribute differently to human perception of different pain 
stimuli (Diatchenko, Nackley et al. 2006). The authors report that COMT diplotypes 
were strongest associated to thermal pain, and that the rate of temporal summation of 
heat pain did not differ among haplotype combinations. In contrast, the common and 
well-studied rs4680 SNP was associated to the rate of temporal summation of heat pain 
(a process mediated by the central nervous system), but not with other pain measures. 
Based on the results from this study, Diatchenko and co-workers suggest that the 
rs4680 SNP in the COMT gene may play a primary role in variation in temporal 
summation of heat pain, but that other SNPs of COMT haplotype exert a greater 
influence on resting nocieptive sensitivity (Diatchenko, Nackley et al. 2006). 
Furthermore, they emphasize the importance of this finding, arguing that these 
assumptions are consistent with two other studies investigating the rs4680 impact on 
pain perception (Zubieta, Heitzeg et al. 2003; Kim, Neubert et al. 2004). Kim et al.,
(Kim, Neubert et al. 2004), report no association between the rs4680 SNP and measures 
of pain sensitivity to transient noxious thermal stimuli (resting nociceptive sensitivity), 
while Zubieta et al., (Zubieta, Heitzeg et al. 2003) report an association between the 
SNP and muscle pain sensitivity evoked by prolonged infusion of hypertonic saline (a 
temporal integration of painful stimuli involving the central nervous system). Whereas 
Diatchenko and co-workers define haplotypes of the COMT gene as high pain 
sensitivity (HPS), average pain sensitivity (APS) and low pain sensitivity (LPS) 
haplotypes (Diatchenko, Slade et al. 2005), Kim and colleagues failed to see any 
association with haplotypes of the COMT gene addressing postsurgical pain. Instead 
they reported an association between a SNP (rs740603) located in intron 1 of the 
COMT gene with post-operative pain ratings (Kim, Lee et al. 2006). The complexity of 
the matter grows even more apparent when considering a recent study of patients 
undergoing arthroscopic shoulder surgery, where the findings of Diatchenko are 
supported (George, Wallace et al. 2008). In this study COMT diplotypes (APS/HPS) 
were associated with higher pre-operative ratings and increased risk of experiencing 
persistent pain following surgery (George, Wallace et al. 2008). 
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In summary, the available evidence is sufficient to conclude that COMT does in fact 
play a role in pain modulation, but it may take time to fully delineate that role (Lacroix-
Fralish and Mogil 2008; Skorpen, Laugsand et al. 2008). 
5.2.2 Variability in the COMT gene and opioid responses
Only a few studies have been carried out in clinical cohorts addressing COMT and 
responses to opioids. In fact, only cancer patients and their response to opioids during 
cancer pain treatment have been investigated. Three studies in this thesis (Paper II-IV), 
address the COMT gene as a likely contributor to the efficacy of morphine in a cancer 
patient cohort with pain. The first study investigating the COMT gene (Paper II) 
suggests that one SNP, the rs4680, influences the opioid efficacy in the treatment of 
cancer pain. The following studies (Paper III and IV) show and discuss a more complex 
genetic contribution from the COMT gene to the efficacy of opioids. A study by Ross 
and co-workers addressing COMT and central side effects in a cancer patient cohort, 
showed that COMT genotypes and a haplotype were associated to drowsiness and 
confusion or hallucinations (Ross, Riley et al. 2008). In contrast to the results from the 
papers addressing COMT in this thesis, morphine doses did not differ between 
genotypes or haplotypes of COMT in the study by Ross and co-workers. Patient cohorts 
in all studies mentioned in this chapter are of similar size, counting approximately 200 
patients. To elucidate the role of COMT and the variability to opioid responses, larger 
sample sized data should be approached. 
5.2.3 Haplotype construction 
Knowledge of an individual’s haplotype is important, given that individual SNPs 
usually influence with a minor contribution to biological functions. Haplotype 
construction enables us to study the overall effect of SNPs and haplotype analyses are 
more powerful tool for studying genetic association to disease or drug response. In 
paper IV we have chosen to construct and present long haplotypes across the entire 
COMT gene. An alternative approach would have been to construct haplotypes defined 
by haploblocks in the gene. Haploblocks are regions in the gene where values of the 
linkage disequilibrium (LD) between SNPs are high (see 1.4 Genetic terms). Analyses 
of LD between SNPs have so far revealed three haploblocks in the COMT gene in 
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cohorts with European ancestry (Diatchenko, Slade et al. 2005; Kim, Lee et al. 2006). 
The long haplotype is defined by the total number of SNPs analysed and is therefore a 
combination of “haploblock-haplotypes” carried on one chromosome. The haplotypes 
defined by haploblocks can be looked upon as bricks in a jigsaw puzzle, but it is only 
when you manage to put the bricks together that you are able to see the whole "picture" 
in the jigsaw puzzle. Therefore, long haplotypes give extra genetic information in 
genetic analyses and to the individuals’ genetic makeup. However, whether genetic 
analyses should select primary outcome of long haplotypes across genes, or rather 
shorter haplotypes constructed from haploblocks, is a question that needs to be debated. 
In this thesis we chose to present long haplotypes of the COMT gene only. Further data 
analyses elucidating the linkage disequilibrium between SNP and presentation of 
haploblock may have been appropriate. However, we would still have been forced to 
choose a primary outcome of the presentation and analyses of genetic groups, to protect 
against multiplicity of testing.   
5.3 Combined effects of genes and opioid efficacy (Paper III) 
Paper III answers the aim of study number three, and investigated the combined effects 
from two SNPs in the OPRM1 and COMT genes. The SNPs, the 118A>G and the 
rs4680, have been suggested in previous papers (Paper I and II) to have a possible 
effect on opioid efficacy. We found that patients being homozygous A/A and Met/Met 
in the OPRM1 and COMT genes, respectively, needed less morphine dose for pain 
relief than other patient groups with other allele combinations of the genes. One other 
study has addressed the gene joint effect of two SNPs in two genes relevant for opioid 
efficacy in a cancer patient cohort (Campa, Gioia et al. 2008), so studies addressing 
possible joint gene effects for the phenotypes of opioid response are (to my knowledge) 
at present only two. While we were addressing joint effects of the OPRM1 and COMT
genes, Campa et al., investigated joint effects of the C3435T SNP in the 
ABCB1/MDR1 gene and the 118 A>G SNP in the OPRM1 gene. Combining the 
extreme genotypes in these genes, Campa and co-workers detected and defined three 
patient groups: Strong responders, responders and non-responders of morphine in a 
cancer patient cohort (Campa, Gioia et al. 2008).
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Epistasis, the interaction between genes, is of major interest in molecular genetics. 
Most researchers today hypothesize that epistasis is an ubiquitous component of the 
genetic architecture, and that it is consequently more important to investigate the 
interactions between genes than the independent effects of any possible susceptibility 
gene (Moore 2003). Most likely, the most important elements for describing the 
phenotype of opioid response are interaction of susceptible genes together with 
important contribution of environmental factors. This plausible complex relation of 
epistasis and environment to opioid response is illustrated in Figure 7. The fact that 
only two studies at present have investigated the combined effect of genes on opioid 
response, demonstrates the scarcity of current research findings. Detection of many 
more genes and biological pathways will obviously be of utmost importance in future 
research.
Figure 7: The relation of epistasis and environmental factors to opioid response. The different sizes of the 
arrows indicate that genes have different effect on the response of opioids. The question mark indicates 
that there are still unknown biological pathways that contribute to the response of opioids. 
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The joint effects of genes can be expected to have a synergistic (enhanced), 
antagonistic (suppressed) or no effect on the phenotype investigated. If epistasis is 
detected, it is often followed by an assumption that it can tell us something about the 
mechanisms and pathways involved in the phenotype investigated, in particular in 
relation to the biological interaction between the implicated proteins (Cordell 2002). 
Any given data pattern from the combined effect of two genes can be obtained from a 
number of different underlying biological mechanisms. Therefore, definite conclusions 
regarding synergistic and antagonistic effects are generally beyond the grasp of an 
association study (Thompson 1991). However, a careful consideration and discussion 
on possible biological mechanisms behind the suggested interaction of the OPRM1 and 
the COMT genes is interesting, and may also bring forward hypotheses suited for 
research in the future. Based on the findings of Zubieta and co-workers (Zubieta, 
Heitzeg et al. 2003), we speculate that the contribution from the genetic variability in 
the COMT gene to the efficacy of morphine is due to a downregulation of μ-opioid 
receptors in various regions of the brain. However, experimental studies, such as in 
vitro cell studies and animal studies are needed to elucidate the role of interaction 
between genes.
The number of classifiable genetic subgroups increases when investigating joint effects 
of polymorphisms in multiple genes. The number of genetic subgroups derived from a 
study investigating two SNPs in two genes is nine. However, in Paper III only four 
genetic groups were created and this was done on the basis of the earlier findings that 
the OPRM1 A/A genotype (Paper I) and the COMT Met/Met genotype (Paper II) 
required the least morphine doses. Carriers of the COMT Met/Met and the OPRM1 A/A 
genotype were defined as one “true” genetic group, while other genetic subgroups were 
merged into one. For example, Met/Met and A/G carriers were merged into one genetic 
group together with Met/Met and G/G carriers, defined as Met/Met but not A/A 
carriers. Defining such merged genetic groups may be a limitation to the study since we 
do not know the contribution of the different genotypes to the possible interaction 
between them. The preliminary findings in Paper III reveal the importance of assessing 
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joint effects of genes, but there is a definite urge for larger samples sizes in future 
studies.
In Paper III the mean morphine dose (117mg/24h) was used to divide groups of low 
morphine dose users (=<117mg/24h) and high morphine dose users (>117mg/24h). A 
question can be raised whether this is the appropriate cut-off between low dose and 
high dose users. A better design would perhaps have been to use 25 % of the patients 
with the lowest doses of morphine and 25 % of the patients with the highest doses of 
morphine. This procedure would have gained a more extreme phenotype, but would 
have reduced the sample size by 50%. Statistical power decreases when sample sizes 
are reduced, followed by the probability of not detecting a statistical significant 
association even if it is present. The importance of measuring the “correct” phenotype, 
however, should always be a priority taken into consideration the simultaneous wish for 
a large sample study.  
5.4 A balanced view of association studies 
Genetic association studies have been the main tool and an important approach in the 
effort to indentify candidate genes and genetic variation underlying the efficacy of 
opioids. The objective of an association study is to seek a statistical association 
between genetic variant(s) and a phenotypic variation. The development of genetic 
medicine the last decades (as illustrated in Figure 1 in the introduction) has made it 
possible to test for more than one million genetic variants in a single experiment. 
Although genotyping technology and genome-wide approaches are available today, it 
has been here for only a short period of time (Iles 2008). To my knowledge the current 
association studies addressing the efficacy of opioids in humans have exclusively used 
a candidate-gene approach, in which one or several genes – hypothesized to be 
involved in the biology of opioid action – are studied. Reviewed in Skorpen and 
Laugsand, a total of 15 candidate genes have been investigated in the search for genetic 
variation contributing to μ-opioid responses (Skorpen, Laugsand et al. 2008).
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Despite early initial optimism for genetic association studies (Risch and Merikangas 
1996), the merit of such studies is now strongly debated (Hirschhorn, Lohmueller et al. 
2002; Ioannidis 2003; Lohmueller, Pearce et al. 2003; Page, George et al. 2003; 
Moonesinghe, Khoury et al. 2007) because of the high proportion of false positive 
findings (Ioannidis 2005). A comprehensive review, carried out in 2002, performed a 
survey of more than 600 positive associations between common gene variants and 
disease. Out of 166 reported associations studied three or more times, only six were 
replicated consistently (Hirschhorn, Lohmueller et al. 2002).  
The purpose of a replication study is to evaluate a positive (or negative) finding from a 
previous study, in order to provide credibility that the initial findings are valid. More 
specifically, a replication study provides insurance against biases and errors (that can 
unavoidably afflict any study), among others inappropriate control groups, investigator 
biases, over-elaborate data exploration, and genotyping errors (Page, George et al. 
2003). A quality assessment of genetic association studies supporting susceptibility for 
acute lung injury has been carried out by Flores and co-workers (Flores, Pino-Yanes 
Mdel et al. 2008). This study investigated 14 criteria, based on a checklist suggested by 
the NCI-NHGRI Working Group on Replication in Association Studies (Chanock, 
Manolio et al. 2007), and scored these criteria as 1 if present and 0 if absent. Of 16 
reported genes associated to acute lung injury, four genes were the most replicated 
across studies, and the studies on average had an intermediate quality score. Attempts 
to assess the quality of the current genetic association studies are of crucial importance 
to the validation of results, but have to my knowledge not been carried through 
addressing pharmacogenetic studies of opioids.
Liu et al., argue that the research field of genomics may have unreasonable high 
expectations of success of replication, and question whether it is sufficient or necessary 
to treat replication as the gold standard for defining true variants (Liu, Papasian et al. 
2008). Functional studies, such as gene expression studies at the RNA level and 
proteomics studies at the protein level, may provide useful and complementary 
information to genetic association studies as they can support (or not support) findings 
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in studies on the DNA level. In other words, such studies may reveal information on 
how the gene(s) contribute to the trait investigated.
In conclusion, a single association study can be considered as a stage on a journey that 
starts with ignorance and hopefully ends with a clear and robust conclusion on whether 
a given gene locus contributes to the trait investigated (Hattersley and McCarthy 2005). 
However, time has come to be more stringent and mature when planning a design for 
an association study. Reasonable criteria for future association studies include the use 
of low P-values, large sample sizes, replication in multiple samples, and avoidance of 
population stratification. Meta-analyses and functional studies are also of importance 
and ideal to guide interpretation of findings from genetic association studies.  
5.5 Unequivocal genotype and phenotype? 
5.5.1 Is the genotype correct?  
SNPs are the most frequent genetic variation in genes, but there are also other 
variations within the DNA sequence, such as microsatellites, short tandem repeats 
(STRs), and insertions and deletions, all of which may have an impact on complex 
phenotypes. DNA methylation, modification of histones and chromatin, and RNA 
interference represent examples of epigenetics and have been suggested to have a 
mechanism of biological heredity, even though these variations are not based on 
variation in the DNA sequence (Pembrey 2002). Recent findings, including copy 
number variation (CNV) (Freeman, Perry et al. 2006; Locke, Sharp et al. 2006; 
McEwen, Woolfe et al. 2006), short transcripts of unknown function (Gingeras 2007), 
and gene-gene interactions describe even more of the complexity in the human genome. 
All the above mentioned genetic variation may mask the effect of any given SNP on a 
complex phenotype. New discoveries of the human genome clearly indicate that a 
genotype of an individual, earlier coined as “an assignment by scientific investigators 
without any room for error”, is more uncertain than expected. Thus, genotype errors are 
most likely present in the majority of published association studies. The term 
unequivocal genotype is replaced by equivocal genotype, and more than three dozen 
factors causing the uncertainty of a genotype have been reported (Nebert, Zhang et al. 
2008). However, analysis of SNPs will continue to be of considerable importance in 
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large-scale genome wide association studies (GWAS) and in large-scale replication 
studies, but a careful discussion and interpretation of the SNPs contribution to the 
complex biological pathway is needed.  
5.5.2 Genetic diversity and ethnic considerations 
In the late 1990s, the term single nucleotide polymorphism (SNP) was defined, 
formerly known as “nucleotide substitution” (Nebert, Zhang et al. 2008). With the 
concurrent improvements in the technology for SNP detection at that time, hundreds of 
publications in the years that followed sought to find associations between one or a few 
SNPs and a multiplex phenotype. SNPs are the most frequent genetic variation in 
genes. At present the number of SNPs in the human genome, released in National 
Center for Biotechnology Information (NCBI) dbSNP Build 129 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi), is nearly 15 million, 
and more than 6 million of theses are validated. Considering only the 6 million 
validated SNPs in the ~ 3 billion base pair long human genome, the rate of SNPs is 1 
per 500 base pair. Only 1.1 % of the genome is spanned by exons, 24 % by introns, and 
75 % of the genome is intergenic DNA (Venter, Adams et al. 2001). Even though any 
two human individuals are more than 99% identical to each other on the basis of DNA 
comparisons, there are many ethnical differences that need to be carefully considered in 
genetic association studies. For example, the rs4680 (Val158Met) polymorphism in the 
COMT gene is reported to vary from 0.01 to 0.62 for the Met allele in a global sample 
population (Palmatier, Kang et al. 1999). Also, despite the relative low genetic 
differentiation among Europeans, a subtle population structure has been discovered 
where genetic variation mirrors the geography of Europe, and an individual’s DNA can 
be used to conclude on the individual’s origin with surprising accuracy (Novembre, 
Johnson et al. 2008).
Another important issue of genetic variability is that SNPs are only one type of genetic 
variation. As mentioned, structural variations of the genome, such as CNVs and 
balanced chromosomal rearrangements (inversions) have gained much attention in the 
field of human genetics. CNVs are recognized to contribute to a major proportion of the 
64
genetic differences in humans and estimated to account for more of the differences seen 
in any two individuals than the differences due to SNPs (Sebat 2007). Global variation 
in CPV has been reported for populations with ancestry in Europe, Africa and Asia 
(Redon, Ishikawa et al. 2006), so awareness for population stratification is needed also 
for CPV studies.
To summarize, the past few years have shown that the variability in the human genome 
is larger then earlier appreciated (Sebat 2007) and the differences between ethnical 
groups are more apparent and more specific than previously known (Novembre, 
Johnson et al. 2008). Therefore, it is important to precisely state the ethnical and 
geographical origin of populations in genetic association studies.
5.5.3 Accuracy in measuring phenotype
Clear clinical descriptions are necessary to define a phenotype unequivocally. In a 
palliative cancer patient cohort treated with opioids, the potential phenotype may be 
any particular response seen after opioid administration. In Paper I, II and IV the 
continuous variable “24 hour morphine dose” is chosen to represent the phenotype 
“morphine requirements to relieve cancer pain”, and in Paper III we divide the patient 
population into groups of high dose morphine users (>117mg/24h) and low dose 
morphine users (<117mg/24h). It can be discussed whether these phenotype definitions 
in the presented papers are unequivocal and “tell the truth” about the requirements of 
morphine for the cancer patients. Taking into consideration the complexity of clinical 
medicine, and even more so the area of pain assessment, it is most likely that there are 
factors in our studies contributing to the lack of an unequivocal phenotype. For instance 
it is evident that the phenotype “pain” may contribute to the need for morphine. 
Unfortunately, some patients in our cohort report too much pain to be considered 
adequately treated with morphine. In Paper I we chose to include only patients 
adequately treated (inclusion criteria being average pain reporting less or equal to 4), to 
protect against the possible “noise” from patients not receiving sufficient doses of 
morphine for their cancer pain. Despite this attempt to make the patient group more 
homogenous, the reported pain was differently distributed between genotype groups 
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(1.9±1.5, 3.1±1.1 and 2.0±1.2 for AA, AG and GG genotype groups respectively), 
illustrating the need to discuss and carefully consider possibly confounding factors to 
the phenotype investigated. In general, confounding factors are seldom easily 
measured, and attempts to protect against them pre study are difficult. Considering the 
palliative cancer patient cohort in this thesis, the effect of opioids can be “hidden” or 
misinterpreted because other cancer disease symptoms influence the patients’ 
assessment of the pain treatment. Is vomiting and nausea caused by the cancer disease 
or the opioid administration? Is a possible untreated depression causing an effect on 
opioid response? We know that there are interactions between other medications and 
opioids, but to which extent is often unknown. More than 18 factors that can cause an 
equivocal phenotype have been suggested (Nebert and Vesell 2004). There will clearly 
be an ever existing challenge to define a “precise” phenotype, and a discussion on 
potential factors’ contribution to the lack of unambiguity in a pharmacogenetic study is 
definitely needed.
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6. Conclusion and future perspectives 
We have investigated two genes and their association to opioid efficacy. Based on our 
findings and the supplementary recent literature, we suggest that both the COMT and 
the OPRM1 genes are important contributors to the analgesic effect of morphine. The 
present thesis can be viewed as the first step on the journey to elucidate genetic 
variations that contribute to opioid efficacy in cancer patients.  
The current literature on the pharmacogenetics of opioids is limited to well-known 
polymorphisms in clear candidate genes, and sample sizes of typically a few to a couple 
of hundreds of individuals (Skorpen, Laugsand et al. 2008). A natural approach in the 
future will be to seek supporting evidence in larger sample sizes, and search for other 
genes that influence on opioid efficacy. A number of different study designs, such as 
family studies, twin studies, and studies in animals, may be applied to identify new 
genes to the list of contributors to opioid response, but genome wide association studies 
(GWAS) are the most likely approach for future studies. A collaboration project with 
11 European countries (EPOS study initialized by our research team) is about to be 
finalized (March 2009) giving a biobank of pharmacological, genetic and clinical data 
of approximately 2300 cancer patients receiving opioids, mostly morphine and 
oxycodon, for pain treatment. The next steps will be to further investigate the enlarged 
cohort of cancer patients in the EPOS collaboration project with a genome-wide 
approach.
In principle, complex phenotypes such as opioid response might be more susceptible to 
“soft” forms of genetic variation, such as variation in non-coding sequences and copy 
number, which alter gene dose without abolishing gene function (McCarroll and 
Altshuler 2007). The genetic variation that contributes to the complex phenotype of 
opioid response is likely to be influenced by non-coding sequences and structural CNV 
of the DNA. To date there are no studies investigating variations of CNV and the 
response to opioids. Future studies addressing CNV and the efficacy of opioids for 
cancer pain will be interesting.  
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In the presented thesis the patient population was treated with morphine for cancer 
pain. Even though morphine is the opioid of choice for moderate to severe cancer pain, 
alternative opioids, such as oxycodon is becoming more frequently used in palliative 
cancer patients. The effect of different opioids may depend on different sets of genes, 
so studies addressing the use of different opioids need to be carried out in the future.
Most cancer patients experience several symptoms that may prevent and/or limit the 
degree of analgesic effect of opioids. Adverse effects such as sedation, nausea and 
vomiting, and euphoria are examples of symptoms that may have a genetic basis. 
Studies mapping the genetic variations influencing the interindividual differences in 
symptom occurrence have just begun, combining large cohort (EPOS study) and 
genome-wide association approaches.    
A doctoral thesis carried through at our research team has validated the pain 
assessments commonly used in palliative care (Hølen 2008). One conclusion from this 
thesis is that better assessment tools for pain measurements are needed (Holen, 
Hjermstad et al. 2006). For self-reported pain assessment, our research team has in a 
collaboration project with the EAPC research network and with an EU grant, started the 
development of a new and improved computer based assessment tool. There are also 
strong initiatives within the palliative care community that there is a need for 
developing an international consensus on how to classify pain in cancer patients (Kaasa 
and Radbruch 2008; Knudsen, Aass et al. 2009). 
Taking into consideration the lack of stringent criteria in published association studies 
and the difficulties defining unequivocal traits and genetic groups, it remains unclear 
whether individualized drug therapy will be achievable by means of DNA testing alone 
(Nebert, Zhang et al. 2008). It is yet too early to arrive at a conclusion about how (and 
when) the “bench research” of genetics approaches the clinic and the patient’s 
“bedside”. However, there is no doubt that translational research will have advantages, 
and is the best approach in future studies.
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Abstract
Catechol-O-methyltransferase (COMT) inactivates dopamine, epinephrine and norepinephrine in the nervous system. A common
functional polymorphism (Val158Met) leads to a three- to-four-fold variation in the COMT enzyme activity, the Met form displaying lower
enzymatic activity. The Val158Met polymorphism affects pain perception, and subjects with the Met/Met genotype have the most
pronounced response to experimental pain. Based on this information we analyzed the inﬂuence from the COMT Val158Met polymorphism
on the efﬁcacy of morphine in a cohort of patients suffering from cancer pain. We genotyped 207 Caucasian cancer patients on morphine
treatment with respect to the Val158Met polymorphism and compared the morphine doses, serum concentrations of morphine and morphine
metabolites between the genotype groups. Patients with the Val/Val genotype (nZ44) needed more morphine (155G160 mg/24 h) when
compared to the Val/Met (117G100 mg/24 h; nZ96) and the Met/Met genotype (95G99 mg/24 h; nZ67) groups (PZ0.025). This
difference was not explained by other factors such as duration of morphine treatment, performance status, time since diagnosis, perceived
pain intensity, adverse symptoms, or time until death. These results suggest that genetic variation in the COMT gene may contribute to
variability in the efﬁcacy of morphine in cancer pain treatment.
q 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Keywords: Pain; Genotyping; Genetic variation; Opioid
1. Introduction
The catechol-O-methyltransferase (COMT) enzyme
metabolizes the catecholamines dopamine, epinephrine
and norepinephrine, and is a key modulator of dopaminergic
and adrenergic neurotransmission. The involvement of
catecholamines in pain modulation is known from clinical
(Ali et al., 2000; Niemi and Breivik, 2002) and experimental
studies (Bie et al., 2003; Raja et al., 1995; Sagen
and Proudﬁt, 1985). It has been shown in animal models
that the neuronal content of enkephalins is reduced by
chronic activation of dopaminergic neurotransmission
(Steiner and Gerfen, 1998). An upregulation of m opioid
receptors in various regions of the brain follows the
reduction of enkephalin content (Chen et al., 1993; Steiner
and Gerfen, 1998). Based on this knowledge, Zubieta et al.
(2003) investigated the relationship between the common
polymorphism Val158Met in the COMT gene and pain
perception and opioid receptor density in volunteers. The
Val158Met polymorphism causes a valine (Val) to meth-
ionine (Met) substitution at codon 158 in the COMT
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enzyme, leading to a three- to four-fold reduced activity of
the enzyme (Lachman et al., 1996; Lotta et al., 1995).
Therefore, the Val/Val, Val/Met and Met/Met genotypes
may predict a high, intermediate and low COMT enzyme
activity, respectively. Zubieta et al. (2003) hypothesized
that enhanced activation of the dopaminergic neurotrans-
mission in individuals with the low-activity COMT enzyme
would result in lower levels of enkephalins, and conse-
quently more pain due to decreased endogenous opioid
analgesia. They conﬁrmed that individuals with the COMT
Met/Met genotype had higher sensory and affective ratings
of pain following an experimental pain stimulus, and also
that individuals with the Met/Met genotype had higher
regional density of m opioid receptors (Zubieta et al., 2003).
Morphine pharmacology is complex and may be
inﬂuenced by genetic variation related to morphine
metabolism, opioid receptors and blood–brain-barrier
transport (Duguay et al., 2004; Klepstad et al., 2004;
Thompson et al., 2000). We have previously reported that
the 118 AOG polymorphism in the m opioid receptor gene
increases morphine requirements in patients with pain
caused by malignant disease (Klepstad et al., 2004). Opioid
efﬁcacy may also be affected by genetic variation in non-
opioid biological systems interacting with opioids. Thus, the
experimental ﬁndings in the study by Zubieta et al. (2003)
prompted us to investigate whether the COMT Val158Met
polymorphism inﬂuences pain in a clinical setting. The
effect of the polymorphism could be hypothesized to be
bidirectional. The patients with the Met/Met genotype have
lower neuronal content of enkephalin, which might lead to
decreased endogenous analgesia and a compensatory
requirement for higher morphine doses. Alternatively, the
demonstrated increase of m opioid receptors might lead to an
increased effect from morphine administration in Met/Met
genotype individuals. Based upon these hypotheses we
analyzed the inﬂuence from the COMT Val158Met
polymorphism on the efﬁcacy of morphine in a population
suffering from cancer pain.
2. Materials and methods
2.1. Ethics
The study was carried out in accordance to the principles of the
Helsinki declaration. The Regional Committee for Medical
Research Ethics, Health Region IV, Norway, approved the study,
and all patients gave their oral and written informed consent before
inclusion in the study.
2.2. Subjects
We analyzed a cancer patient population included (from June
1999 to February 2000) in a study originally designed for assessing
the relationship between patients’ characteristics and serum
concentrations of morphine and metabolites (Klepstad et al.,
2003). All patients were Caucasians and in-patients at the 900-bed
tertiary St Olav University Hospital in Trondheim, Norway,
receiving scheduled oral morphine for cancer pain treatment.
The following information was collected from the hospital
records for each patient: age, gender, ethnicity, cancer diagnosis,
time since diagnosis and time since start of morphine. The daily
morphine doses were collected from the patients’ ward charts.
Survival times from the time of inclusion were obtained from the
death records of Norway.
2.3. Assessments
Pain was measured using the item ‘average pain‘ during the last
24 h in the Brief Pain Inventory (BPI) questionnaire. The patients
rated pain on an 11-point numeric scale, where 0 represents ‘no
pain’ and 10 represents ‘pain as bad as you can imagine’. The BPI
is developed for the use in cancer pain patients, validated in
Norwegian, and recommended by the European Association of
Palliative Care for use in clinical studies (Caraceni et al., 2002;
Daut et al., 1983; Klepstad et al., 2002). The European
Organization for Research and Treatment of Cancer core quality-
of-life questionnaire (EORTC QLQ-C30) version 3.0 was used to
assess the patients’ nausea/vomiting, constipation, fatigue and
tiredness (Aaronson et al., 1993). Cognitive function was assessed
with the Mini Mental State (MMS) examination. The MMS score
ranges from 0 to 30, higher scores meaning better cognitive
function (Folstein et al., 1975). The patients’ functional status was
assessed by the Karnofsky performance status (Karnofsky et al.,
1948).
2.4. Blood samples and pharmacogenetic analyses
Collection of blood samples and determination of serum
concentration of morphine and its metabolites (morphine-
6-glucuronide and morphine-3-glucuronide) were done as described
in a previous work from our group (Klepstad et al., 2003). Genomic
DNAwas isolated from 50 to 200 ml EDTA blood on aMagNA Pure
LC (Roche Diagnostics Scandinavia AB, Bromma, Sweden) using
theMagNAPure LCDNA Isolation Kit I applying themanufacturers
high performance protocol. Puriﬁed genomic DNA was eluted in
100 ml elution buffer and stored atK20 8C.
COMT genotypes were determined using the LightCycler
(Roche Diagnostics Scandinavia AB, Bromma, Sweden) ﬂuor-
escence resonance energy transfer method (Wittwer et al., 1997).
Polymerase chain reaction (PCR) ampliﬁcations were performed in
20 ml reactions on a LightCycler System, using 2 ml puriﬁed
genomic DNA and the LightCycler-FastStart DNA Master
Hybridization Probes kit (Roche Diagnostics Scandinavia AB,
Bromma, Sweden). PCR primers (Eurogentec, Seraing, Belgium)
Table 1
Primers and hybridization probes used for Val158Met genotyping
Sequence
Primers Forward 5 0-ACGCCGTGATTCAGGAGCA-30
Reverse 5 0-GTCTTTCCTCAGCCCCAG-3 0
Probes Sensor 5 0-TCACGCCAGCGAAATCCA-Fl-30
Anchor 5 0 LC Red 640-ATCCGCTGGGT-
GATGGCG-3 0
*Fl, ﬂuorescein; LC Red 640, Light Cycler Red 640. Bold C indicates
polymorphic site.
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and ﬂuorescence labeled probes (PROLIGO, Paris, France) are
shown in Table 1. Conditions for PCR and melting curve analyses
are shown in Table 2. The Val158Met polymorphism was veriﬁed
using standard DNA sequencing methods as described previously
(Holthe et al., 2003).
2.5. Statistical analysis
Descriptive data are given as mean (SD). Because the COMT
alleles are expected to be codominant with respect to total COMT
enzyme activity, we expected a gene-dose effect of the Val158Met
polymorphism in respect to the need for morphine. In other words,
we expected the morphine doses of the Val/Met heterozygous
carriers to be in-between the morphine doses of the Val/Val and
Met/Met homozygous carriers. Comparisons between the different
genotypes were therefore performed with the Jonckheere–Terpstra
test, a non-parametric test working with the hypothesis that
m1%m2%m3 (or the opposite m1Rm2Rm3) (Hollander and Wolfe,
1999).
Post Hoc tests were performed with Mann–Withney U-tests. A
P-value less than 0.05 was considered statistical signiﬁcant.
A prestudy formal sample size calculation was not performed
since the data material and the number of patients originally was
collected for a different study (Klepstad et al., 2003). The statistical
software SPSS for Windows v. 11.5 was used for all statistical
analyses.
3. Results
3.1. Patients
Two hundred and seven patients receiving chronic oral
morphine treatment for cancer pain were included in the
study. The patients’ gender distribution, age, primary tumor
locations, Karnofsky performance status, time since diag-
nosis, time since morphine treatment started and time from
inclusion until death are shown for each genotype in
Table 3. We observed no differences between the various
genotype groups (Val/Val, Val/Met and Met/Met) for these
patients’ characteristics. We observed no differences in the
pain intensity between the three genotype groups (Table 4).
The intensities of other symptoms such as fatigue, nausea
and vomiting, dyspnea, sleep disturbance, loss of appetite
and constipation were similar between the three groups
(Table 4). The patients’ cognitive function measured by
MMS sum score was similar between the groups (Table 4).
We also observed no differences in renal and hepatic
functions as assessed by serum creatinine concentrations
and serum albumin concentrations between the three
genotype groups (Table 3). All patients were Caucasians.
3.2. Genotype distributions
The observed genotype frequencies were 44, 96 and 67
for the Val/Val, Val/Met and Met/Met, respectively
(Table 5). The relative frequency of the Met allele was
0.56, which is in the upper range of known allele
frequencies in European populations (Biomed European
Bipolar Collaborative Group, 1997). The Val158Met
polymorphism distribution for the 207 cancer patients was
in Hardy–Weinberg equilibrium (c2Z0.767; PZ0.381).
Table 2
Ampliﬁcation and melting curve conditions for COMT genotypes
PCR cycling conditions Melting curve conditions
Denaturation Annealing Extension Cycles Stepwise temp.
decrease
Temp. increase
95 8C for 15 s 62 8C for 15 s 72 8C for 14 s 10 90 8C for 15 s; 66 8C,
58 8C and 40 8C for
20 s each
From 40 to 90 8C
at 0.4 8C/s95 8C for 15 s 60 8C for 15 s 72 8C for 14 s 14
95 8C for 15 s 56 8C for 15 s 72 8C for 14 s 20
Temp, temperature.
Table 3
Patient demographics for Val158Met genotype groups
Val/Val
(nZ44)
Val/Met
(nZ96)
Met/Met
(nZ67)
Gender male: female 24:20 55:41 38:29
Age 65 (11) 64 (13) 61 (13)
Tumor diagnosis
Urologic 10 32 17
Lung 8 17 14
Breast 9 20 16
Gastrointestinal 6 10 3
Others 11 17 17
Karnofsky
performance status
67 (10) 65 (14) 70 (12)
Creatinine serum
(mmol/l)
86 (34) 83 (25) 88 (40)
Albumin serum (g/l) 31 (5) 33 (6) 33 (5)
Time since diagnosis
(months)
35 (49) 41 (50) 38 (47)
Time since morphine
treatment started
(months)
3.7 (6.1) 3.4 (6.1) 3.3 (8.4)
Survival time after
study (months)a
5.5 (6.0) 4.9 (5.2) 5.8 (6.5)
All numbers are absolute numbers or mean (SD). No statistically signiﬁcant
differences were observed between groups. Categorical data were analyzed
using the chi-square test, and continuous variables were evaluated with
One-Way ANOVA if homogeneity tests were not signiﬁcant. Kruskal
Wallis test was used when homogeneity tests resulted in signiﬁcant values.
a Survival times from the time of inclusion were obtain from the total
number of patients with the Val/Val genotype, nZ41; Val/Met genotype,
nZ85; and Met/Met genotype, nZ61.
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3.3. Pharmacological observations
There were signiﬁcant differences between the genotype
groups when comparing morphine doses. Patients with the
Val/Val genotype (nZ44) received 155G160 mg/24 h
morphine, patients with the Val/Met genotype received
117G100 mg/24 h (nZ96) and patients with the Met/Met
genotype received 95G99 mg/24 h (nZ67) (Jonkcheere–
Terpstra test, PZ0.025). Post Hoc Mann–Whitney tests
showed that patients with the Val/Val genotype received
signiﬁcantly higher daily morphine doses when compared to
patients with the Met/Met genotype (PZ0.03), while the
heterozygous Val/Met group did not reach statistically
signiﬁcant difference when compared to the other genotype
groups (Table 6).
The observed mean serum concentrations of morphine,
M6G and M3G were higher in patients homozygous
Val/Val than in patients heterozygous Val/Met, and higher
in patients heterozygous than in patients homozygous
Met/Met. These observations did not reach statistically
signiﬁcant levels (Jonckheere–Terpstra test: morphine
serum concentration, PZ0.85; M6G serum concentration,
PZ0.06; M3G serum concentration, PZ0.14) (Table 6).
Because the Jonckheere–Terpstra tests did not indicate
statistical signiﬁcant differences as deﬁned by a P-value
O0.05, no post hoc tests were performed.
4. Discussion
We have addressed a possible contribution of the COMT
Val158Met polymorphism to inter-individual variation in
morphine requirements among patients suffering from
cancer pain. The patients with the Val/Val genotype needed
more morphine when compared to patients with the
Met/Met genotype.
Several studies have shown that the dose of morphine
required to achieve adequate pain control varies between
patients. A three-fold variation in morphine doses has been
observed among patients at similar stage of cancer pain (start
of step III treatment at theWHOpain ladder) (Klepstad et al.,
2000b). The inter-individual differences observed for serum
concentrations of morphine and morphine metabolites are
more pronounced than the inter-individual difference in
morphine doses (Klepstad et al., 2000a). This observation
indicates that variable pharmacokinetics is not the sole factor
contributing to the variable need for morphine. Epidemio-
logical observations suggest that genetic dispositions are
important for this inter-individual variability in opioid
pharmacodynamics as exempliﬁed by that Native Americans
have amore pronouncedmorphine induced depression of the
ventilatory response compared with Caucasians (Cepeda
et al., 2001), and Caucasians have shown to become more
sedated and to exhibit a more depressed ventilatory response
than Asians (Zhou et al., 1993).
The complexity of morphine pharmacology suggests that
the variability in opioid pain treatment is associated with
genetic variation in several genes. Genes that may inﬂuence
the efﬁcacy of morphine include the UGT2B7 gene (Duguay
et al., 2004), which product is responsible for morphine
metabolism, the OPRM1 gene encoding the m opioid
receptor (Klepstad et al., 2004; Lotsch et al., 2002), and
the MDR1 gene (Thompson et al., 2000) encoding the
P-glycoprotein which may be involved in the transport of
morphine across the blood–brain-barrier.
Non-opioid systems such as the adrenergic system may
also inﬂuence on opioid analgesia. Both clinical (Ali et al.,
2000; Niemi and Breivik, 2002) and experimental studies
(Bie et al., 2003; Raja et al., 1995; Sagen and Proudﬁt, 1985)
Table 4
Patient symptoms for Val158Met genotype groups
Val/Val
(nZ44)
Val/Met
(nZ96)
Met/Met
(nZ67)
BPI average pain 3.9 (2.2) 3.7 (2.6) 3.5 (2.3)
Fatigue EORTC score 73 (23) 62 (24) 66 (22)
Nausea and vomiting
EORTC score
30 (27) 24 (26) 29 (27)
Dyspnea EORTC score 39 (35) 38 (34) 32 (33)
Sleep EORTC score 35 (34) 34 (36) 35 (35)
Appetite EORTC score 64 (36) 49 (38) 53 (38)
Constipation EORTC score 56 (41) 57 (37) 54 (37)
Mini mental examination
sum score
26 (4) 26 (3) 26 (4)
All numbers are mean (SD). No statistically signiﬁcant differences were
observed between groups (One-Way ANOVA). Kruskal Wallis test was
used when homogeneity tests resulted in signiﬁcant values.
Table 5
COMT genotype and allele frequencies in the total of 207 cancer patients
Genotype frequencies Allele frequencies
Val/Val Val/Met Met/Met Val Met
N 44 96 67 184 230
Relative
frequencies
0.21 0.47 0.32 0.44 0.56
Table 6
Pharmacological observations for Val158Met genotype groups
Val/Val
(nZ44)
Val/Met
(nZ96)
Met/Met
(nZ67)
Morphine dose (mg/24 h)a,b 155 (160) 117 (100) 95 (99)
Morphine serum (nmol/l) 119 (199) 86 (88) 78 (72)
M6G serum (nmol/l) 711 (992) 506 (493) 410 (484)
M3G serum (nmol/l) 3809 (4436) 2812 (2209) 2536 (2707)
All numbers are mean (SD). No statistically signiﬁcant differences were
observed for the other observations (PZ0.06 for differences in M6G conc.;
PZ0.14 for differences in M3G conc.; PZ0.85 for differences in morphine
conc.).
a (Jonkcheere–Terpstra test); PZ0.025.
b Post Hoc Mann–Whitney tests; PZ0.03 for differences between Val/
Val and Met/Met genotype groups.
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have shown an improved analgesic effect of opioids with the
concomitant use of catecholamines. COMT is the main
enzyme metabolizing the catecholamines dopamine,
epinephrine and norepinephrine. In vitro analysis of COMT
enzyme activity has shown that the Val158Met polymorph-
ism in the COMT gene affects the thermostability of the
enzyme. TheMet form is thermolabile, displaying a three- to
four-fold reduced activity at 37 8C compared to the Val form
of the enzyme (Lotta et al., 1995). However, the activity
of the Met variant was normalized by cofactors like
S-Adenosyl-L-methionine and magnesium (Lotta et al.,
1995). The implications of a putative stabilizing effect of
these compounds on COMT activity in vivo are not
established.
It has been shown from animal studies that the neuronal
content of enkephalins is reduced by chronic activation of
dopaminergic neurotransmission (Steiner and Gerfen,
1998). The reduction of enkephalin content is followed by
an up-regulation of m opioid receptor density in various
regions of the brain (Chen et al., 1993; Steiner and Gerfen,
1998). Variable COMT enzyme activity may alter dopa-
minergic activity and could therefore, through an altered
action of dopaminergic substances, inﬂuence on the
enkephalin content and opioid receptor density. Zubieta
et al. (2003) observed that volunteers with the Met/Met
genotype had a lower tolerance to pain and a higher regional
m opioid receptor density compared with individuals with
Val/Met and Val/Val genotype. In the present study we
observed that cancer patients with the Met/Met genotype
needed lower doses of morphine in order to relieve pain
compared with patients with the Val/Val genotype. This
observation is intriguing as individuals with the Met/Met
genotype also had low tolerance to pain (Zubieta et al.,
2003). One possible explanation for our observation of
lower morphine requirements in cancer pain patients with
the Met/Met genotype could be that an increase of m opioid
receptor density causes morphine to be more effective in
individuals carrying this genotype.
Opioid tolerance is well established in experimental
models (Portenoy, 1994) but the signiﬁcance of tolerance
with respect to the efﬁcacy of morphine during chronic
cancer pain treatment is difﬁcult to reproduce in clinical
studies (Collin et al., 1993). Tolerance development with
down-regulation of m opioid receptors could be argued to
counteract the increase in receptor density associated with
the Met/Met COMT genotype. We collected data from a
cohort of patients were the mean duration of morphine
treatment in the three genotype groups ranged from 3.3 to
3.7 months, and there was no statistical difference between
the genotype groups in respect to the duration of morphine
treatment (Table 3). Hence, our results suggest that the
inﬂuence of COMT variability on morphine need, if due to
receptor density, is not confounded by the possible
development of opioid tolerance.
We recognize some limitations in our study. Cancer
patients represent a heterogeneous patient group prone to be
inﬂuenced from several possible confounders. The severity
of the disease and the nociceptive stimuli will vary between
patients, patients might have variable organ function, and the
treatment with other drugs can give rise to drug interactions.
To check whether the genotype groups were different with
regard to factors that might inﬂuence morphine requirements
we compared the different genotype groups for several
characteristics associated with the severity of the malignant
disease such as time since diagnosis, time since morphine
treatment started, performance status and time from study
inclusion until death. The different genotype groups showed
similar results for these characteristics as for other possible
confounders including age, gender, renal function and liver
function (Table 3).We chose a clinical research design in this
study, including individuals receiving chronic morphine
treatment for cancer pain. We believe that studies examining
the effect of genetic variation in a clinical setting are
important because they provide information that is not easily
obtained in studies performed in controlled experimental
settings. Simply stated, the clinical studies answer whether
genetic variation is of clinical signiﬁcance.
In this study we observed statistically signiﬁcant differ-
ences in morphine doses between genotypes, but not for the
serum concentrations of morphine and its metabolites.
However, there was a trend towards an increase in serum
concentration of M6G when comparing the genotype groups;
the Met/Met, Val/Met and Val/Val genotypes displayed the
lowest, intermediate and highest serum concentration,
respectively. This trend is likely to reﬂect the same biological
effect of the Val158Met polymorphism as seen with the
morphine doses. In general, the inter-individual variation of
serum concentrations is more pronounced than for the
morphine doses, and consequently an increased number of
patients are needed for an observed difference to reach
statistical signiﬁcance. In future studies a prestudy sample size
calculation should be performed to calculate the sample size
needed in order to compensate for the variability of serum
concentrations and hence avoid the risk of a type II error.
Pain is a trait with a complex genetic basis, and most
likely the efﬁcacy of analgesics is inﬂuenced by a number of
genes. Therefore, this study cannot determine the relative
importance of the Val158Met polymorphism compared to
other variations in genes that are likely to inﬂuence on the
requirement of morphine. The results of the present study
suggest that the Val158Met polymorphism in the COMT
gene may contribute to the variability in clinical efﬁcacy of
morphine when administered to cancer pain patients. This
ﬁnding is of principle interest since it demonstrates that
genetic variability in genes relevant to non-opioid systems
can inﬂuence the clinical efﬁcacy of opioids.
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Abstract
Pain is a complex human trait. It is likely that the interaction of multiple genes, each with a small individual eﬀect, along with the
eﬀect of environmental factors, inﬂuences the clinical eﬃcacy of opioids rather than a single gene alone. Polymorphisms in genes
coding for the mu-opioid receptor (A118G) and catechol-O-methyl transferase (Val158Met) may be important modulators of opioid
eﬃcacy. We assessed joint eﬀects of the OPRM1 and COMT genes in predicting morphine dose for cancer pain relief. We used geno-
type and clinical data from a pharmacokinetic study of morphine in 207 inpatients treated with stable morphine dose for at least 3
days by Palliative Medicine Specialists. Results showed signiﬁcant variation in morphine dose requirement by genotype groups: car-
riers of COMT Val/Val and Val/Met genotype required 63% and 23%, respectively, higher morphine dose compared to carriers of
Met/Met genotype (p = 0.02). Carriers of OPRM1 GG genotype required 93% higher morphine dose compared to carriers of AA
genotypes (p = 0.012). When we explored for joint eﬀects, we found that carriers of the OPRM1 AA and COMTMet/Met genotype
required the lowest morphine dose to achieve pain relief (87 mg/24 h; 95%CI = 57,116) and those with neither Met/Met nor AA
genotype needed the highest morphine dose (147 mg/24 h; 95%CI = 100,180). The signiﬁcant joint eﬀects for the Met/Met and
AA genotypes (p < 0.012) persisted, even after controlling for demographic and clinical variables in the multivariable analyses.
Future studies are needed to further characterize the joint eﬀects of multiple genes, along with demographic and clinical variables,
in predicting opioid dose.
 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cancer pain is one of the most persistent and inca-
pacitating symptoms of cancer. While opioids remain
the drug of choice for cancer pain therapy (World
Health Organisation Geneva, 1996) with morphine
as the ﬁrst line drug of choice, predicting the optimal
morphine dose for patients remains a challenge.
While traditionally, this inter-individual variability
has been explained by diﬀerences in bioavailability,
metabolism, diﬀerences in pain perception and other
neurophysiological mechanisms, and socio cultural
factors, evidence now suggests an important role of
genetic variability in the clinical eﬃcacy of opioids
0304-3959/$32.00  2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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* Corresponding author. Tel.: +1 713 792 1816; fax: +1 713 792
0807.
E-mail address: creyes@mdanderson.org (C.C. Reyes-Gibby).
www.elsevier.com/locate/pain
Pain 130 (2007) 25–30
(Pasternak, 2001; Lotsch et al., 2004; Klepstad et al.,
2005).
As the most important target for morphine, poly-
morphisms of the gene for the mu opiod receptor
(OPRM1) located on human chromosome 6q24-q25
(Wang et al., 1994), are primary candidates for genetic
inﬂuences on the eﬃcacy of opioids (Uhl et al., 1999;
Hoehe et al., 2000; Koch et al., 2000; LaForge et al.,
2000; Befort et al., 2001; Wang et al., 2001). Numer-
ous single nucleotide polymorphisms (SNPs) in the
OPRM1 gene have been identiﬁed, but only a few
have been explored for a possible relevance in opioid
analgesia, including the A118G (Lotsch and Geissling-
er, 2006b).
The inﬂuence of the polymorphic catechol-O-methyl-
transferase (COMT) gene located on chromosome 22
(22q11.21) to pain has been an active area of investiga-
tion. The Val158Met polymorphism, a common genetic
variant, has been shown to inﬂuence the activity of the
COMT enzyme. The enzyme, which metabolizes the cat-
echolamines dopamine, epinephrine and norepineph-
rine, is also key modulator of dopaminergic and
adrenergic neurotransmission.
Polymorphisms in genes coding for the OPRM1
(Bond et al., 1998; Befort et al., 2001; Wang et al.,
2001; Lotsch et al., 2002; Klepstad et al., 2004; Fillin-
gim et al., 2005; Lotsch and Geisslinger, 2006b) and
COMT (Lachman et al., 1996; Zubieta et al., 2003;
Shield et al., 2004; Rakvag et al., 2005) may be impor-
tant modulators of opioid eﬃcacy. Pain is a complex
human trait and it is likely that the interaction of mul-
tiple genes, each with a small individual eﬀect, along
with the eﬀect of environmental factors, inﬂuences the
clinical eﬃcacy of opioids rather than a single gene
alone.
The purpose of this study was to explore the joint
eﬀects of genes previously shown to have inﬂuence on
the clinical eﬃcacy of morphine in a sample of cancer
patients receiving morphine treatment for cancer pain.
We speciﬁcally assessed joint eﬀects of variation in the
OPRM1 and the COMT genes in predicting morphine
dose for pain control.
2. Patients and methods
We used data from the study of Klepstad et al. (2004)
and Rakvag et al. (2005) that includes genotyping data
and clinical variables for 207 patients admitted for cancer
pain treatment. All patients were Caucasians and in-
patients during the period June 1999 to February 2000 at
St. Olav University Hospital, a 900-bed tertiary hospital
in Trondheim, Norway. Patients were treated with stable
morphine dose for at least 3 days before inclusion in the
pharmacokinetic study of morphine. Patients aged <18,
those not competent in the Norwegian language and those
refusing consent to the study, were not included in the
study.
Patients’ hospital records were reviewed for age, gender,
cancer diagnosis, time since diagnosis, presence of metastases
and time since start of morphine. Clinical and laboratory vari-
ables including serum albumin and creatinine levels, and mor-
phine dose for the last 24 h were abstracted from the patients’
medical charts.
2.1. Pain assessment
Pain was measured using the item of ‘average pain’ dur-
ing the last 24 h in the Brief Pain Inventory (BPI). The
patients rated pain on an 11-point numeric scale, where 0
represents ‘no pain’ and 10 represents ‘pain as bad as you
can imagine’. Recommended by the European Association
of Palliative Care (Caraceni et al., 2002) for use in clinical
studies of pain, the BPI has been validated in Norwegian
(Klepstad et al., 2002). The patients’ functional status was
assessed by the Karnofsky performance status (Yates
et al., 1980; Mor et al., 1984).
2.2. Blood sample, DNA extraction and genotyping
Collection of blood samples was described previously
(Klepstad et al., 2004). Brieﬂy, genomic DNA was isolated
from 50 to 200 ml EDTA blood on a MagNA Pure LC
(Roche Diagnostics Scandinavia AB, Bromma, Sweden) using
the MagNA Pure LC DNA Isolation Kit I applying the
manufacturer’s high performance protocol. Puriﬁed genomic
DNA was eluted in 100 ml elution buﬀer and stored at K20
8C.
The procedure for genotyping was described previously
(Klepstad et al., 2004; Rakvag et al., 2005).
2.3. Ethics
The study was conducted in accordance with the principles
of the Helsinki Declaration and was approved by the Regional
Committee for Medical Research Ethics, Health Region IV,
Norway. Patients gave their oral and written informed consent
before inclusion in the study.
2.3.1. Statistical analyses
We performed univariate comparisons of genotype frequen-
cies using the v2 test. Comparisons across alleles for speciﬁc
genotypes were performed using analysis of variance.
We conducted multivariable logistic regression analyses
using morphine dose as the dependent variable. We used mean
morphine dose (117 mg/24 h) to divide the groups
(low = <117 mg/24 h; high > 117 mg/24 h). Given the explor-
atory nature of this study, we did not assume gene-dose eﬀect
and instead created dummy variables for the diﬀerent geno-
types. The ﬁrst model included all the variables found signiﬁ-
cant at p < 0.20 in the univariate level of analysis. A p value
of 0.20 was used as the cut-oﬀ since using a more traditional
level (p < 0.05) often failed to identify variables known to be
important (Bendel and Aﬁﬁ, 1977). Further variable selection
in the model was conducted by using backward elimination.
With the goal of having the most parsimonious model, only
variables with p < 0.05 were included in the ﬁnal model. Colin-
earity diagnostics were also performed. The Statistical Package
for Social Sciences was used in all the analyses (SPSS, 1998).
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3. Results
Two hundred and seven patients, aged 29–89 years
(mean age = 63), receiving chronic morphine treatment
for cancer pain were included in this study. There were
more males than females (56% versus 44%). The most
common type of cancer was urologic (28%), followed
by breast (22%) and lung (19%). Ninety percent of the
sample had metastatic disease. Mean duration of mor-
phine use was 3.4 months (SD = 6.9) and duration (time
since cancer diagnosis) of cancer was from 0.4 to 50
months (mean = 24 months; SD = 48).
Patients received from 10 mg to 760 mg/24 h of mor-
phine (mean = 117 mg/24 h; SD = 116 mg/24 h). The
median pain score for the whole sample was 4. There
were no statistically signiﬁcant diﬀerences in pain inten-
sity scores.
3.1. Genotype analyses
Allele frequencies and the results of the v2 test for sep-
aration from Hardy-Weinberg equilibrium showed that
there was no signiﬁcant departure from Hardy-Weinberg
equilibrium for COMT Val158Met(23) and OPRM1
A118G (A = 0.888; G = 0.111; v2 = 0.29; p = 0.91).
The total morphine dose, median and mean pain
intensity by polymorphisms (Panel A) and genotype
combination (Panel B) are shown in Table 1. There were
no statistically signiﬁcant diﬀerences in pain scores
across genotypes and joint genotype combination. Panel
A shows that carriers of Val/Val and Val/Met genotype
required 63% and 23%, respectively, higher morphine
dose compared to carriers of Met/Met genotype
(p = 0.02). For the OPRM1 gene, GG and AG genotype
required 93% and 18%, respectively, higher morphine
dose compared to carriers of AA genotypes [carriers of
AA relative to GG (p = 0.012)].
Panel B shows the total morphine dose, median and
mean pain intensity by joint genotype combination.
Since carriers of the COMT Met/Met and the OPRM1
AA genotypes required the least morphine dose, we cre-
ated the following 4 groups: (1) Met/Met and AA; (2)
Met/Met but not AA; (3) AA but not Met/Met; and
(4) neither Met/Met nor AA. We observed statistical sig-
niﬁcance for the joint eﬀects of Met/Met and AA geno-
types (p < 0.017). We did not observe statistically
signiﬁcant diﬀerences for the other groups, which could
be explained by the large variation in morphine dose for
those groups.
3.2. Multivariable regression analyses
We assessed if the joint eﬀects of COMT and
OPRM1 genotype on morphine dose will persist, con-
trolling for variables known to potentially confound
the relationship. Demographic variables such as age
and gender and clinical variables such as Karnofsky sta-
tus, time since cancer diagnosis and months using mor-
phine and creatinine and albumin levels were included in
the model. Variables found in the univariate analysis to
be signiﬁcantly associated with morphine dose at a level
of p < 0.20 (Bendel and Aﬁﬁ, 1977) were next entered
into a multivariate logistic regression analysis with the
purpose of building a model to determine the predictive
Table 1
Total morphine dose (mg/24 h) and pain outcomes by genotype (Panel A) and joint genotype combination (Panel B)
Genotype Morphine
dose mg/24
Mean
95%CI Pain scores***
Pain intensity
Median Mean (SD)
Panel A*
COMT
Val/Val (n = 44) 155 106; 203 4 3.94 (2.2)
Val/Met (n = 96) 117 97; 137 3 3.66 (2.6)
Met/Met (n = 67) 95 71; 119 3.5 3.46 (2.3)
OPRM1
AA (n = 166) 112 96; 128 3 3.60 (2.6)
AG (n = 36) 132 76; 187 4 4.10 (1.8)
GG (n = 5) 216 60; 371 2 2.0 (1.2)
Panel B**
Met/Met & AA (n = 58) 87 57; 116 3 3.18 (2.3)
AA but not Met/Met (n = 108) 126 104; 147 4 4.89 (1.8)
Met/Met but not AA (n = 9) 140 72; 224 5 3.83 (2.6)
Neither Met/Met nor AA (32) 147 100; 180 3 3.48 (1.8)
OPRM1, mu opioid receptor 1; COMT, cathechol-O-methyltransferase.
* Statistically signiﬁcant diﬀerence for mean morphine dose for carriers of AA relative to GG (p = 0.012). Statistically signiﬁcant diﬀerence for
mean morphine dose for carriers of Val/Val relative Met/Met (p = 0.023).
** Statistically signiﬁcant diﬀerence for mean morphine dose for carriers of Met/Met and AA relative to Neither Met/Met nor AA (p = 0.017).
*** No statistically signiﬁcant diﬀerences for pain intensity scores by genotype groups.
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value of genotype on morphine dose. Results showed
joint Val158Met and A118G genotypes, months using
morphine and time since cancer diagnosis as signiﬁcant
variables in predicting morphine dose. Table 2 shows
that even after controlling for clinical variables, we
observed statistical signiﬁcance for the joint eﬀects of
COMT Met/Met and OPRM1 AA (p < 0.012) on mor-
phine dose. We also conducted multivariable linear
regression analyses, with morphine dose as a continuous
variable (analyses not shown). We observed statistical
signiﬁcance for the joint eﬀects of COMT Met/Met
and OPRM1 AA (p < 0.012) on morphine dose.
4. Discussion
This study examined the potential joint eﬀect of genes
in predicting the clinical eﬃcacy of morphine for cancer
pain treatment and control. A number of studies have
looked at the joint eﬀects of genes in diseases like asth-
ma (Hong et al., 2005), diabetes (Bergholdt et al., 2005;
Maier et al., 2005), prostate (Xu et al., 2005) and lung
cancer (Zhang et al., 2006), Alzheimer’s disease (Infante
et al., 2004), heart disease (Ye et al., 2003). The joint
eﬀects of genes can be expected to enhance, suppress
or have no eﬀect on the phenotypic outcome of interest.
Our ﬁndings provide empirical support for the impor-
tance of joint eﬀects of the OPRM1 and COMT gene in
the clinical eﬃcacy of morphine. We have shown that
carriers of Met/Met and AA genotype in the COMT
and OPRM1 gene, respectively, needed less morphine
dose for pain relief, thus providing preliminary support
for the potential use of genetic data in predicting mor-
phine dose for adequate control of pain in cancer
patients. To our knowledge this is the ﬁrst study to have
looked at the joint eﬀects of genes in opioid analgesia.
Recent debates on the assessment of candidate genes
for pain and pain-related traits have focused on the need
for a polygenic model for these complex phenotypes.
Ideally, many genes with functional signiﬁcance should
be assessed. We selected the OPRM1 and the COMT
variants in this study because of the strength of previ-
ously published associations of these genes with pain
and pain-related phenotypes and the minor allele fre-
quencies (Hoehe et al., 2000; Mayer and Hollt, 2001).
Human studies showed the importance of the A118G
polymorphism in pain and pain-related phenotypes. Fil-
lingim and colleagues showed that the A118G polymor-
phism was associated with pressure pain sensitivity
(Fillingim et al., 2005) and a recent study by Lotsch
and Geisslinger (2006b) also showed that the A118G
polymorphism is an important target for understanding
variability in opioid eﬃcacy as observed in human
experimental pain models. We extended these ﬁndings
by providing preliminary evidence of the eﬀects of
A118G polymorphism in the clinical eﬃcacy of opioids
and its joint eﬀects with Val158Met.
That pain and pain-related phenotypes may also be
modulated by the function of several endogenous sub-
stances such as adrenergic and noradrenergic neurotrans-
mitters has also been shown in previous studies. Steiner
and Gerfen (1998) found that the neuronal content of
enkephalins is reduced by chronic activation of dopami-
nergic neurotransmission, which is followed by an up-reg-
ulation of mu-opioid receptor density in various regions
of the brain (Chen et al., 1993; Steiner and Gerfen,
1998). Variable COMT enzyme activity may therefore
alter dopaminergic activity and could, through an altered
action of dopaminergic substances, have an inﬂuence on
the enkephalin content and opioid receptor density.
Diatchenko and colleagues (2005) found haplotypes
of the gene encoding COMT and found signiﬁcant asso-
ciations between the COMT haplotypes and pain sensi-
tivity. Zubieta and colleagues found that Val158Met
polymorphisms were associated with several pain phe-
notypes such as mu opioid system responses and higher
sensory and aﬀective ratings of pain (Zubieta et al.,
2003). Homozygosity for the Met158 allele was associat-
ed with diminished regional mu-opioid system responses
to pain and increases in l-opioid receptor binding
potential (Zubieta et al., 2003). The increase in the den-
sity of opioid receptors in those with Met/Met allele
may therefore result in an improved eﬃcacy of mor-
phine. Rakvag et al. (2005) found that Val158Met poly-
morphism in the COMT gene is a signiﬁcant predictor
of morphine dose requirements for treatment of cancer
pain. In this study, we found that COMT Val158Met
had joint eﬀects with the A118G polymorphisms in the
OPRM1 gene.
Table 2
Logistic regression model for morphine dose
Parameter p-value Odds ratio 95% Lower bound 95% Upper bound
Joint genotype groups* 0.05
a. Met/Met & AA 0.012 0.278 0.102 0.756
b. AA but not Met/Met 0.280 0.625 0.266 1.467
c. Met/Met but not AA 0.191 0.240 0.028 2.039
Months using morphine 0.005 1.106 1.031 1.186
Time since cancer diagnosis (in months) 0.006 0.988 0.980 0.987
Morphine dose (low = 6117 mg/24 h; high > 117 mg/24 h).
* Reference variable is Neither Met/Met nor AA. Candidate variables included months using morphine, time since cancer diagnosis, age, sex,
Karnofsky performance status, serum albumin, serum creatinine.
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Klepstad et al. (2004) and Rakvag et al. (2005)
assumed a gene-dose eﬀect on univariate analyses, with
carriers of OPRM1 GG allele and COMT Val/Val allele
associated with a higher morphine dose. However, we
did not assume a gene-dose eﬀect in the multivariate
model, given the exploratory nature of this study.
Future studies are needed to assess if there are gene-dose
eﬀects in the relationship between OPRM1 and COMT
genotypes and opioid eﬃcacy.
We found that the duration of morphine treatment
was an important predictor for morphine dose. It is pos-
sible that this time interval is reﬂective of the progres-
sion of disease, i.e., as patients progressed in their
disease, they required higher morphine dose. Another
explanation is that repeated administration of morphine
leads to the need for higher dose or the need for opioid
rotation. A known mechanism for this phenomenon is
the reduction in the responsiveness of the G-protein cou-
pled opioid receptors (Nestler, 1992) leading to either
desensitization or downregulation. More recently the
concept of paradoxical pain leading to analgesic toler-
ance has also been proposed (King et al., 2005).
There are limitations to this study. Arguably the
design of our study may be associated with several bias-
es, such as the heterogeneity of our study population.
Another limitation is that the data were already previ-
ously analyzed for the individual eﬀects of the OPRM1
and the COMT variant. Nonetheless the present analy-
ses point to the importance of assessing the joint eﬀects
of genes on pain and pain-related phenotypes.
We also recognize that the complexity of morphine
pharmacology suggests that the variability in opioid
pain treatment is associated with genetic variation
in several genes (Mogil, 1999; Mogil et al., 2000;
Thompson et al., 2000; Flores and Mogil, 2001; Belfer
et al., 2004; Duguay et al., 2004; Kim et al., 2004;
Max, 2004; Diatchenko et al., 2005; Stamer et al.,
2005; Lee et al., 2006; Lotsch and Geisslinger, 2006a).
Despite major improvement in pain control over the
last 15 years, cancer-related pain continues to be a sig-
niﬁcant public health concern. Morphine is recom-
mended as a ﬁrst line strong opioid (World Health
Organisation Geneva, 1996). The appropriate use and
the ability to predict the optimal dose of opioids for
cancer patients are crucial aspects for the eﬀective
treatment and management of cancer pain. Previous
studies have focused on disease-related variables, clini-
cal health status and sociodemographic characteristics
in understanding adequate treatment and control of
pain. Advances in molecular technology have now
made it possible to assess the contribution of genes
in pain treatment and control. Our observation that
genetic diﬀerences inﬂuence clinical eﬃcacy of mor-
phine may prove useful in managing patients who
receive these drugs, and importantly, preventing nega-
tive responses due to inappropriate dosing. Because
pain is prevalent not just in cancer patients but in other
diseases, the COMT and OPRM1 genotypes may be
relevant information to consider when implementing
pain therapy.
In conclusion, our preliminary ﬁndings suggest the
importance of assessing joint eﬀects of genes in studies
of clinical eﬃcacy of morphine. Future studies with larg-
er cohorts are needed to further characterize the joint
eﬀects of multiple genes, along with demographic and
clinical variables, in predicting opioid dose.
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Abstract
Background: Genetic variation contributes to differences in pain sensitivity and response to
different analgesics. Catecholamines are involved in the modulation of pain and are partly
metabolized by the catechol-O-methyltransferase (COMT) enzyme. Genetic variability in the
COMT gene may therefore contribute to differences in pain sensitivity and response to analgesics.
It is shown that a polymorphism in the COMT gene, Rs4680 (Val158Met), influence pain sensitivity
in human experimental pain and the efficacy for morphine in cancer pain treatment. In this study
we wanted to investigate if variability in other regions in the COMT gene also contributes to
interindividual variability in morphine efficacy.
Results: We genotyped 11 single nucleotide polymorphisms (SNPs) throughout the COMT gene,
and constructed haplotypes from these 11 SNPs, which were in Hardy-Weinberg equilibrium. We
compared both genotypes and haplotypes against pharmacological, demographical and patient
symptoms measurements in a Caucasian cancer patient cohort (n = 197) receiving oral morphine
treatment for cancer pain. There were two frequent haplotypes (34.5% and 17.8%) in our cohort.
Multivariate analyses showed that patients carrying the most frequent haplotype (34.5%) needed
lower morphine doses than patients not carrying the haplotype, with a reduction factor of 0.71 (p
= 0.005). On the allele level, carriers of alleles for six of the SNPs show weak associations in respect
to morphine dose and the alleles associated with the lowest morphine doses constitute part of the
most frequent haplotype.
Conclusion: This study suggests that genetic variability in the COMT gene influence the efficacy of
morphine in cancer patients with pain, and that increased understanding of this variability is reached
by expanding from analyses of single SNPs to haplotype construction and analyses.
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Background
One of the genes in which variability is believed to con-
tribute to differences in pain sensitivity and response to
analgesics is the catechol-O-methyltransferase (COMT) gene
[1-3]. The COMT enzyme metabolises catecholamines
such as dopamine, noradrenaline and adrenaline. The
most studied single nucleotide polymorphism (SNP) in
the COMT gene is the Rs4680, also known as Val158Met.
This polymorphism causes a substitution from a valine
(Val) to a methionine (Met) at amino acid position 158,
leading to a three- to four-fold reduced activity of the
COMT enzyme [4]. Because of the influence on COMT
activity by the Rs4680 (Val158Met) SNP and the well
established involvement of catecholamines in pain per-
ception [5-7], several studies have investigated if this SNP
can explain interindividual variability in pain perception
and efficacy of analgesics. Zubieta et al., demonstrated
that individuals with the Met/Met genotype had higher
sensory and affective ratings of pain and a higher regional
density of mu opioid receptors in the brain [1]. The
Rs4680 (Val158Met) SNP has also been shown to influ-
ence efficacy of morphine used for cancer pain, for which
the Met/Met genotype group needed lower morphine
doses than Val/Val genotype group [2]. Results from these
two studies are intriguing since individuals with the Met/
Met genotype report higher pain ratings, but need less
morphine. However, as authors discuss [2], the increase of
mu opioid receptor density seen in Met/Met genotype
individuals [1], may explain why morphine is more effec-
tive in individuals carrying this genotype.
Other researchers have investigated other SNPs across the
COMT gene and shown that other regions of the gene may
also contribute to pain perception [3,8] and influence
morphine-related side-effects [9]. Diatchenko et al., iden-
tified three genetic variants (haplotypes) in the COMT
gene and designated them as low pain sensitivity (LPS),
average pain sensitivity (APS) and high pain sensitivity
(HPS) haplotypes. The Rs4680 (Val158Met) polymor-
phism was one of four SNPs included in their haplotype
analyses. The authors argue that the Rs4680 (Val158Met)
SNP cannot account for the observed variations in pain
perception alone, since both the LPS and HPS haplotypes
possess the G allele that codes for the more stable Val var-
iant of the COMT enzyme [3]. Kim et al., analysed 13
SNPs in the COMT gene and their association to acute
post-surgical pain in humans [8]. The authors found that
the Rs740603 polymorphism showed significant associa-
tion with maximum post-operative pain rating, but did
not observe any association between other SNPs, includ-
ing the Rs4680 (Val158Met) SNP, and pain score. Ross et
al., found that a SNP in intron 1 (Rs740603) and a haplo-
type, defined by SNPs in the promoter region and intron
1, were significantly associated with drowsiness and con-
fusion or hallucinations in a cancer patient cohort treated
with morphine. In the study by Ross et al., the Rs4680
(Val158Met) SNP did not influence the risk for morphine
induced adverse effect [9].
All the three studies cited above that have investigated
multiple SNPs in the COMT gene have either pain percep-
tion or the risk for opioid adverse effects as the primary
endpoint in the study [3,8,9]. No studies have investi-
gated if other SNPs than the Rs4680 (Val158Met) in the
COMT gene are important for the analgesic efficacy of
morphine. Therefore, in a patient cohort in which we have
previously shown that the Rs4680 (Val158Met) polymor-
phism influences the efficacy of morphine for cancer pain
[2], we investigated if variability in other regions in the
COMT gene also contribute to interindividual variability
in morphine efficacy. In addition to examining the effect
from each individual SNP we constructed long haplotypes
in order to study composite effect from combinations of
11 SNPs along the gene.
Results
DNA from 197 patients receiving oral morphine treat-
ment for cancer pain was analysed in this study.
Genotype and haplotype distribution
A schematic presentation of the 11 SNPs analysed in the
COMT gene is shown in Figure 1. The genotype frequen-
cies, allele frequencies and allele carriage for all 11 SNPs
analysed are shown in Table 1. All SNPs were in Hardy-
Weinberg equilibrium. The long haplotypes constructed
from the 11 SNPs in the COMT gene are shown in Table
2. The frequencies of the two most common haplotypes
were 34.5% and 17.8%. Fourteen different haplotypes
with a frequency of > 1% described 91% of the popula-
tion. We designated the haplotypes as haplotype 1 to hap-
lotype 14, corresponding to the frequency at which they
occur; haplotype 1 being the most frequent.
Morphine dose and genotypes
The pharmacological observations for genotype groups
and allele carriage are shown in Table 3. The median mor-
phine dose requirements between genotype groups for the
Rs4818 polymorphism were 60, 80 and 120 mg/24 h for
the CC, CG and GG genotype groups, respectively (p =
0.042) and for the Rs4680 (Val158Met) polymorphism
the median morphine doses were 90, 80 and 60 mg/24 h
for the GG, GA and AA genotype groups, respectively (p =
0.022). For six of the SNPs (Rs5746849, Rs740603 in
intron 1, Rs6269 in intron 2, Rs2239393 in intron 3 and
Rs4818 and Rs4680 (Val158Met) in exon 4) allele carriers
showed a tendency to differences in median morphine
doses. (Table 3).
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Morphine dose and haplotypes
We observed that carriers of haplotype 1, the most fre-
quent haplotype in this Caucasian population (Table 2),
needed less morphine than non-carriers, with a median
morphine dose of 60 mg/24 h for carriers versus 100 mg/
24 h for non-carriers (p = 0.006) (Table 4a). The serum
concentrations of morphine, morphine-6-glucuoride
(M6G) and morphine-3-glucuronide (M3G) reflected the
different morphine doses between haplotypes, but no dif-
ferences were statistically significant (Table 4b).
Patient symptoms including average pain, fatigue, nausea
and vomiting, dyspnea, sleep, appetite, constipation and
cognitive function were similar for carriers and non-carri-
ers of haplotype 1 (Table 5). Also the patient characteris-
tics age, gender, tumour diagnosis, performance status,
creatinine and albumin serum concentration, time since
morphine treatment started and survival time after study
were similar between the two genetic groups (Table 6). We
observed that the carriers of haplotype 1 have had the can-
cer diagnosis longer (45 months) than non-carriers of
Table 1: Catechol-O-methyltransferase (COMT) genotype frequencies, allele frequencies and allele carriage in the total of 197 cancer 
patients
SNP (region) Genotype Genotype frequencies Allele Allele frequencies Allele carriage
Rs2075507* AA 0.26 A 0.53 0.80
(promoter) AG 0.54 G 0.47 0.74
GG 0.20
Rs737866 AA 0.61 A 0.78 0.94
(intron 1) AG 0.33 G 0.22 0.39
GG 0.06
Rs7287550 CC 0.53 C 0.72 0.91
(intron 1) CT 0.38 T 0.28 0.47
TT 0.09
Rs5746849 GG 0.18 G 0.43 0.68
(intron 1) GA 0.49 A 0.57 0.82
AA 0.33
Rs740603 AA 0.31 A 0.56 0.81
(intron 1) AG 0.50 G 0.44 0.69
GG 0.19
Rs6269 AA 0.40 A 0.62 0.84
(intron 2) AG 0.44 G 0.38 0.60
GG 0.16
Rs2239393 AA 0.40 A 0.62 0.84
(intron 3) AG 0.44 G 0.38 0.59
GG 0.16
Rs4818 CC 0.41 C 0.63 0.84
(exon 4) CG 0.43 G 0.37 0.59
GG 0.16
Rs4680 (Val158Met) GG 0.22 G 0.44 0.66
(exon 4) GA 0.44 A 0.56 0.78
AA 0.34
Rs174699 CT 0.09 C 0.04 0.09
(intron 5) TT 0.91 T 0.96 100.0
Rs165728 CT 0.10 C 0.05 0.10
(untranslated region) TT 0.90 T 0.95 100.0
* Rs2075507 has recently been revised, earlier SNP number was Rs2097603
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haplotype 1 (31 months) (p = 0.03; Table 6). However
there were no differences in time since morphine treat-
ment started between carriers and non-carriers of haplo-
type 1 (3.4 and 3.6 months respectively; p = 0.47).
In a multivariate stepwise linear regression analysis the
variables "time since morphine treatment started" and
haplotype 1 were shown to influence the morphine dose
(p = 0.001 and p = 0.005; Table 7). After adjusting for the
variable "time since morphine treatment started", the car-
riers of haplotype 1 still require lower morphine doses
than patients that do not carry haplotype 1. Time since
morphine treatment started is positively associated to
morphine dose, whereas the carriers of haplotype 1 is pre-
dicted to need lower doses of morphine than non-carriers
of haplotype 1 with a reduction factor of 0.71 (see discus-
sion for calculation).
Discussion
We have identified a frequent haplotype (haplotype 1) in
the COMT gene that may influence the morphine dose
requirements in cancer patients with pain. Patients who
carry haplotype 1 need lower morphine doses to relieve
pain than patients that do not carry this haplotype (p =
0.006). The carriers of haplotype 1 are also carriers of the
A allele for the Rs4680 (Val158Met) polymorphism,
which is in agreement with our earlier observation that
carriers of the Met variant of the enzyme (= A allele) need
lower morphine doses than carriers of the Val variant of
the COMT enzyme [2]. However, the effect of the A allele
for the Rs4680 (Val158Met) polymorphism is not seen for
haplotype 3 (Table 4a).
The Rs4680 (Val158Met) polymorphism is the most stud-
ied SNP in the COMT gene because the valine (Val) to
methionine (Met) substitution leads to a three-to four-
fold reduced activity of the COMT enzyme [4], hence the
Val/Val, Val/Met and Met/Met genotypes predict a high,
intermediate and low COMT enzyme activity, respec-
tively. As the COMT enzyme metabolises catecholamines,
a low COMT enzyme activity could result in an enhanced
activation of dopaminergic neurotransmission. It is
shown in animal models that the neuronal content of
enkephalin peptides is reduced by chronic activation of
dopaminerg neurotransmission [10]. Pain sensitivity is
affected by the neuronal content of enkephalin, and
reduction in the enkephalin content is shown to be fol-
lowed by an upregulation of mu opioid receptors [11].
Taken together, this can explain the influence from varia-
tion in the COMT gene on the effect of opioids in pain
treatment.
We also observed that carriers of alleles for six of the SNPs
analysed, the Rs5746849 and Rs740603 polymorphism
in intron 1, the Rs6269 polymorphism in intron 2, the
Rs2239393 polymorphism in intron 3 and the Rs4818
and Rs4680 (Val158Met) polymorphisms in exon 4 were
weakly associated to morphine dose (Table 3). The alleles
associated with the lowest morphine dose requirements
constitute part of the SNP sequence in haplotype 1, which
seems reasonable since haplotype 1 is associated with
lower morphine dose requirements in this patient cohort.
The SNPs defining a haplotype may have functional
effects on a protein if the amino acid code is changed [4],
and synonymous SNPs may have effects on the secondary
structure of mRNA [12], that could alter mRNA stability
and/or the translation of a protein [13]. SNPs may also be
associated to a phenotype without having any effects nei-
ther on the protein nor the mRNA, if it is closely linked to
another SNP exerting the real effect on the protein or
Schematic diagram of the COMT geneFigure 1
Schematic diagram of the COMT gene. Schematic diagram of the catechol-O-methyltransferase (COMT) gene, labeled with 
the 11 SNPs analysed in the present study. *Rs2075507 has recently been revised, the former SNP number was Rs2097603. 
Exon 1 and exon 2 are non-coding.
Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
Page 6 of 12
(page number not for citation purposes)
Table 3: Pharmacological observations.
SNP Genotype Morphine dose mg/24 h median 
[range]
P value Allele carriage Morphine dose mg/24 h Median 
[range]
P value
Rs2075507 AA 90 [20–420] 0.220 A 80 [20–760] 0.90
AG 70 [20-480] Not A 60 [10–660]
GG 60 [10–660] G 70 [10–760] 0.09
Not G 90 [20–420]
Rs737866 AA 70 [10–660] 0.486 A 73 [10–760] 0.26
AG 80 [20–760] Not A 90 [20–350]
GG 90 [20–350] G 80 [20–760] 0.45
Not G 70 [10–660]
Rs7287550 CC 70 [20–760] 0.862 C 78 [10–760] 0.59
CT 80 [10–410] Not C 120 [30–420]
TT 120 [30–420] T 80 [10–420] 0.91
Not T 70 [20–760]
Rs5746849 GG 115 [20–420] 0.103 G 80 [20–420] 0.57
GA 80 [20–390] Not G 65 [10–760]
AA 65 [10–760] A 70 [10–760] 0.03c
Not A 115 [20–420]
Rs740603 AA 70 [10–760] 0.099 A 70 [10–760] 0.04c
AG 80 [20–390] Not A 110 [20–420]
GG 110 [20–420] G 80 [20–420] 0.92
Not G 70 [10–760]
Rs6269 AA 70 [20–660] 0.090 A 70 [10–660] 0.03c
AG 75 [10–480] Not A 120 [20–760]
GG 120 [20–760] G 80 [10–760] 0.32
Not G 70 [20–660]
Rs2239393 AA 70 [20–660] 0.093 A 70 [10–660] 0.03c
AG 73 [10–480] Not A 120 [20–760]
GG 120 [20–760] G 80 [10–760] 0.42
Not G 70 [20–660]
Rs4818 CC 60 [10–660] 0.042 a C 70 [10–660] 0.04c
CG 80 [20–480] Not C 120 [20–760]
GG 120 [20–760] G 80 [20–760] 0.04c
Not G 60 [10–660]
Rs4680 (Val158Met) GG 90 [20–760] 0.022 b G 80 [10–760] 0.045c
GA 80 [10–480] Not G 60 [20–660]
AA 60 [20–660] A 70 [10–660] 0.07
Not A 90 [20–760]
Rs174699 CT 80 [20–480] 0.666 C 80 [20–480] 0.67
Not C 73 [10–760]
TT 73 [10–760] T 80 [10–760] -
Not T -
Rs165728 CT 80 [20–480] 0.457 C 80 [20–480] 0.46
Not C 70 [10–760]
TT 70 [10–760] T 80 [10–760] -
Not T -
a Kruskal-Wallis test for 3 independent samples; b Jonckheere Tepstra test for 3 independent samples; c Mann-Whitney U test for 2 independent 
samples.
Pharmacological observations for genotype groups and allele carriage.
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Table 4: Pharmacological observations I % II
a – Pharmacological observations I.
Morphine dose and haplotype groups
Haplotype Carriage N Morphine dose mg/24 h median [range] P value
1 Yes 114 60 [10–660] 0.006 a
No 83 100 [20–760]
2 Yes 61 80 [20–410] 0.94
No 136 70 [10–760]
3 Yes 31 90 [20–420] 0.44
No 166 78 [10–760]
4 Yes 24 70 [20–420] 0.94
No 173 80 [10–760]
5 Yes 17 120 [20–760] 0.17
No 180 78 [10–660]
6 Yes 17 120 [30–200] 0.56
No 180 73 [10–760]
7 Yes 10 120 [40–290] 0.44
No 187 80 [10–760]
N = number of patients
a Mann-Whitney U test for independent samples.
b – Pharmacological observations II.
Serum concentration of morphine, M6G and M3G against haplotype groups
Haplotype Carriage N Morphine (nmol/ml) median [range] M6G (nmol/ml) median [range] M3G (nmol/ml) median [range]
1 Yes 114 51 [2–350] 310 [10–2660] 1810 [120–16200]
No 83 59 [3–1070] 349 [20–4830] 2310 [110–21250]
2 Yes 61 50 [3–330] 346 [20–2482] 1890 [120–12390]
No 136 60 [2–1070] 319 [10–4830] 2040 [110–21250]
3 Yes 31 67 [5–320] 310 [29–1690] 2200 [197–7780]
No 166 50 [2–1070] 330 [10–4830] 1992 [110–21250]
4 Yes 24 51 [3–277] 380 [20–2482] 2213 [110–12390]
No 173 57 [2–1070] 320 [10–4830] 1992 [120–21250]
5 Yes 17 80 [4–1070] 403 [20–4830] 2415 [110–21250]
No 180 52 [2–519] 325 [10–2660] 1960 [120–16200]
6 Yes 17 90 [9–230] 470 [120–1105] 3118 [1017–5481]
No 180 50 [2–1070] 318 [10–4830] 1890 [110–21250]
7 Yes 10 50 [6–220] 460 [81–1809] 1832 [490–9460]
No 187 58 [2–1070] 330 [10–4830] 2020 [110–21250]
N = number of patients; M6G = Morphine-6-glucuronide; M3G = Morphine-3-glucuronide
No statistical differences between carriers and non-carriers of the different haplotype groups for morphine, M6G and M3G serum concentration
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mRNA. The exact contribution from each SNP in haplo-
type 1 to the observed effect on morphine requirements in
the present study is not known.
In the paper we have constructed long haplotypes across
the entire COMT gene. An alternative approach would
have been to construct haplotypes defined by haploblock
boundaries. The latter approach is based on including
only SNPs that have a very high probability of being
inherited together (visualized by the value of D' or r2
which are correlation factors between SNPs) and as a con-
sequence limiting the gene distance to which SNPs catego-
rize into haplotypes. According to literature the COMT
gene consists of at least three haploblocks in Caucasians
[3,14] and there is consistency between ethnic groups, so
the haploblocks is likely to be present also in a Norwegian
population. The division of genes into haploblocks limits
the number of haplotypes present in the population and
thereby increases the number of individuals that fall into
each different haplotype group. When analysing long hap-
lotypes across the entire gene fewer individuals in the
population will be carriers, but more information will be
gained from the effect of combination of SNPs and in that
sense long haplotypes may be more biologically relevant.
Any sizes of haplotypes will be of more scientifically inter-
ests than analyses of SNPs considered one by one.
A cancer population is a heterogeneous group and prone
to be influenced from several possible confounders such
as severity of disease, organ dysfunction and treatment of
other drugs. Therefore, we analysed for possible con-
founding factors that could influence the need for mor-
phine in cancer pain. We found no differences between
carriers and non-carriers of haplotype 1 for patients'
Table 5: Patient symptoms.
Haplotype 1 P value a
Carriers Non-carriers
BPI average pain 3.5 (2.6) 3.9 (2.2) 0.26
Fatigue (EORTC score) 64.5 (23.5) 68.6 (23.1) 0.28
Nausea and vomiting (EORTC score) 26.6 (25.9) 27.0 (28.5) 0.77
Dyspnea (EORTC score) 36.6 (32.5) 34.4 (34.7) 0.80
Sleep (EORTC score) 35.3 (36.0) 32.8 (35.2) 0.58
Appetite (EORTC score) 53.2 (37.6) 54.3 (37.2) 0.95
Constipation (EORTC score) 54.5 (37.9) 55.7 (38.4) 0.77
Mini mental examination sum score 26.1 (3.4) 25.6 (4.0) 0.66
a Mann-Whitney U test for 2 independent samples
Patient symptoms for carriers and non-carriers of haplotype 1.
Table 6: Patient demographics.
Haplotype 1 P value
Carriers Non-carriers
Age 63 (13) 64 (12) 0.68
Gender:
Male 68 (60%) 44 (53%) 0.38
Female 46 (40%) 39 (47%)
Tumour diagnosis:
Urological 38 19 0.80
Lung 20 17
Breast 25 19
Gastrointestinal 7 10
Haematological 10 6
Others 14 12
Karnofsky performance status 67 (14) 66 (13) 0.36
Creatinine serum (Pmol/l) 86 (28) 87 (39) 0.48
Albumin serum (g/l) 33 (5) 32 (5) 0.12
Time since diagnosis (months) 45 (52) 31 (43) 0.03a
Time since morphine treatment started (months) 3.4 (7.8) 3.6 (5.9) 0.47
Survival time after study (months) 5.7 (6.2) 4.8 (5.5) 0.23
Numbers in the table are given as mean (SD) or absolute numbers (%)
a Mann-Whitney U test for 2 independent samples
Patient demographics for carriers and non-carriers of haplotype 1.
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symptoms or for patients' demographics, except from the
time since diagnosis. There was a tendency that carriers of
haplotype 1 have had a cancer diagnosis for a longer time
than non-carriers of the haplotype (Table 6). Theoreti-
cally, patients with a diagnosis for a long time (that is the
patients carrying the haplotype 1) should need more mor-
phine due to more advance cancer disease. In our cohort
the carriers of haplotype 1 need less morphine than non-
carriers. Thus, a potential bias from the skewed distribu-
tion of time since cancer diagnosis is that the observed dif-
ference between haplotypes is lower that the true
difference between haplotypes. However, in order to fur-
ther explore if time since diagnosis was an independent
predictor of morphine dose we included potential con-
founding factors in a multivariate analysis. This analysis
showed that only "haplotype 1" and "time since mor-
phine treatment started" were predictors for morphine
dose. Regression analysis is usually linear, where b is the
slope of the graph and gives the change in value of one
outcome (e.g. morphine dose), per unit change in the
other (e.g. months of morphine treatment). In our regres-
sion the association is not linear because we used the log-
arithm (log10) of the 24 hour morphine dose as the
dependent variable. Therefore, for each month of mor-
phine treatment, the predicted 24 hour morphine dose
increases by a factor of 10(b × months) which translates to
that the dose on average increases by 43% every 12
months (100.013 × 12). Patient carrying haplotype 1 is pre-
dicted to need less morphine to relieve pain than a patient
not carrying haplotype 1, with a reduction factor of 10(b)
= 10(-0.147) = 0.713. In other words, if a patient, not carry-
ing haplotype 1 need 100 mg of morphine to relieve pain,
a patient carrying haplotype 1 is predicted to need 71 mg
of morphine to relieve similar pain. The difference we
observe in the median morphine dose between non-carri-
ers and carriers of haplotype 1 is of similar order of mag-
nitude, 100 mg versus 60 mg of the 24 hour morphine
dose respectively (Table 4a). Experimental studies includ-
ing healthy volunteers give more controlled experimental
conditions due to less potential confounders. However,
clinical studies including cancer patients, such as this
study and the study by Ross et al.,[9] are needed to observe
if genetic variability do influence morphine treatment in
the patients actually receiving the drug. The best effort in
a clinical population is therefore to include potential con-
founders in the analyses and interpret findings within the
clinical context.
Ross et al., analysed the COMT gene and its association
with the central side effects of morphine in a cancer
patient cohort. They found that a haplotype present in
10.4% of the population was associated to drowsiness
and confusion or hallucination [9]. SNPs in the promoter
region and in the intron 1 region define this haplotype
and the authors suggest that it is this region of the COMT
gene that is of interest in order to explain clinical effect
from the COMT enzyme. Alterations in the promoter and
intronic region of the gene can influence the regulation of
gene expression. Therefore, polymorphisms in these
regions might be as important as functional SNPs in cod-
ing regions. The Ross study did not find any associations
between the Rs4680 (Val158Met) polymorphism and
central side effects of morphine [9]. Haplotype 1 in the
present study is not identical to the haplotype that Ross
and co-authors observed to be associated to central side
effects of morphine. However, the haplotypes identified
as important by Ross et al., and haplotype 1 in our study
are related as 7 of 10 possible SNP positions from the
Rs5746849 polymorphism in intron 1 to the UTR' region
carry the same allele and both haplotypes carry the A
allele at the Rs4680 (Val158Met) polymorphism. An
explanation for the discrepancy of the haplotypes might
be that efficacy for pain relief and risks of adverse effects
have different relationships to genotypes.
The need for morphine is a result of both the efficacy of
morphine and influenced by the patients' pain percep-
tion. Patients can experience variable pain from a given
nociceptive stimuli. Therefore genetic variability related to
opioid efficacy as studied in the present study is closely
linked to genetic variability related to pain perception.
Diatchenko et al., have investigated COMT gene variabil-
ity and association to pain responses [3]. They identified
three haplotypes in the COMT gene strongly associated to
pain sensitivity and they designated the different haplo-
types as low pain sensitivity (LPS), average pain sensitivity
(APS) and high pain sensitivity (HPS) haplotypes. Four
SNPs (Rs6269, Rs4633, Rs4818 and Rs4680) constitute
these haplotypes, of which three of the SNPs (Rs6269,
Rs4818 and Rs4680) are included in our analyses. How-
ever, Diatchenko et al., did not include the region in
intron 1 or the promoter regions, the region which the
study by Ross and co-authors [9] believe to be the func-
tional region of interest in the COMT gene. A direct com-
parison with our study is difficult because we have
included 11 SNPs in our haplotype analyses while Diatch-
enko et al., focused on four SNPs. Kim et al., have also
Table 7: Regression analysis. Morphine dose regression analysis
b SE P value
Haplotype 1 -0.147 0.051 0.005
Time since morphine treatment started 0.013 0.004 0.001
Constant 1.95 0.042
The logarithm (log10) of the 24 hour oral morphine dose was the 
dependent variable in this regression analysis. The regression 
coefficient, b, is an estimate of the parameter beta. SE = standard 
errors
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investigated COMT gene variability and association to
pain responses and found that the Rs740603 SNP was
associated with maximum post-operative ratings of pain.
Even though the comparison between Diatchenko et al.,
[3] and Kim et al., [8] with our findings is important, it is
also complicated because we investigate the morphine
efficacy while they are studying the genetics of pain sensi-
tivity. However, one agreement between the different
studies is that the Rs4680 (Val158Met) polymorphism is
not the sole explanation of why COMT seem to contribute
to the effect on pain perception or opioid efficacy as first
reported by Zubieta et al., [1] and Rakvag et al., [2], respec-
tively.
In the present study the serum concentrations of mor-
phine, morphine-6-glucuoride (M6G) and morphine-3-
glucuronide (M3G) reflected the different morphine
doses between haplotypes (Table 4b), but did not reach
statistical significance as seen for the morphine dose. The
interindividual variation of serum concentrations is more
pronounced than for the morphine doses. Consequently,
a larger effect size or an increased number of patients are
needed to reach a statistical significance for an observed
difference between serum concentrations.
Numerous SNPs have been detected in the COMT gene
and 22 of the most frequent SNPs have been analysed
regarding different aspects of pain and opioid responses
[2,3,8,9], so the analyses of 11 SNPs in our study do not
cover all genetic variation in the COMT gene. However, as
many SNPs are tightly linked within haploblocks, most
genetic variability is captured if the selections of SNPs are
chosen to represent the different haploblocks building the
entire gene [15], which is done in the present study.
In the present study we have carried out several compari-
sons. Multiple test correction, as the Bonferroni, is used
when tests are independent and is therefore highly con-
servative. In a genetic association study where SNPs usu-
ally are partly linked to each other, as is the case for the
COMT gene, a conservative multiple test correction lead
to missing real differences [16,17]. Also, in our study the
haplotype analyses is the primary outcome and then as a
consequence we do not consider all null hypotheses to be
of equally importance [17]. In addition to the haplotype
analyses, differences at genotype level and allele level are
presented in this study, but differences at 0.01 < p < 0.05
are interpreted with caution and reported as weak associ-
ations between genetic groups.
Conclusion
This study suggest that genetic variability in the COMT
gene influence the efficacy of morphine in cancer pain
patients, and that increased understanding of this varia-
bility is reached by expanding from analyses of single
SNPs to haplotype constructions and analyses.
Materials and methods
Ethics
The study was carried out in accordance to the principles
of the Helsinki declaration. The Regional Committee for
Medical Research Ethics, Health Region IV, Norway,
approved the study. All patients gave their oral and writ-
ten informed consent before inclusion in the study.
Subjects
We investigated the same cohort as previously described
by Rakvag et al., [2]. Two hundred and seven patients were
included in the original study, but blood for further
genetic analyses was not available for 10 patients. There-
fore, 197 patients were available for further genotyping
and included in our analyses. All 197 patients were Cau-
casians, and all received scheduled oral morphine for can-
cer pain treatment.
Assessments
Pain was measured using the item "average pain" during
the last 24 hours in the Brief Pain Inventory (BPI) ques-
tionnaire. The patients rated pain on an 11-point numeric
scale, where 0 represents "no pain" and 10 represents
"pain as bad as you can imagine". The BPI is developed for
the use in cancer pain patients, validated in Norwegian,
and recommended by the European Association of Pallia-
tive Care for use in clinical studies [18-20]. The European
Organization for Research and Treatment of Cancer core
quality-of-life questionnaire (EORTC QLQ-C30) version
3.0 was used to assess the patients' nausea/vomiting, con-
stipation, fatigue, sleep, appetite and dyspnea [21]. Cog-
nitive function was assessed with the Mini Mental State
(MMS) examination. The MMS score ranges from 0 to 30,
higher scores meaning better cognitive function [22]. The
patients' functional status was assessed by the Karnofsky
performance status [23]. Survival time, time since start of
morphine, cancer diagnoses and opioid doses were
obtained from the patients' hospital records.
Blood samples and pharmacogenetic analyses
Collection of blood samples and determination of serum
concentration of morphine and its metabolites (mor-
phine-6-glucuronide and morphine-3-glucuronide) were
done as described in a previous work from our group [24].
Creatinine serum concentrations and albumin serum con-
centrations were measured using standard analytical
methods.
The genotyping was performed at the Clinical Genomics
Group, Imperial College in London, UK. The selection of
SNPs for this study and primer sequences for sequence
specific polymerase chain reaction (SSP-PCR) are
Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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described in a study by Ross and co-authors investigating
another cohort and another primary outcome [9]. The
selection was based upon frequency of SNP, position in
gene and what was known in the literature at the time
research was planned. Of the 13 polymorphic SNPs
included in Ross and co-authors' study, the rs174680 and
the rs7290221 polymorphisms in intron 1, were not ana-
lysed in our patient cohort due to very tight linkage with
the rs7287550 polymorphism and the rs5746849 poly-
morphism respectively. As the reaction of the Rs4633 pol-
ymorphism did not work very well, we excluded this
polymorphism in the present study, but included the
Rs4818 polymorphism in exon 4, which had not been
analysed in the previous Ross study. Together, 11 SNPs
were genotyped in the present study.
Genomic DNA was isolated from 50 to 200 PL EDTA
blood on a MagNA Pure LC (Roche Diagnostics Scandina-
via AB, Bromma, Sweden) using the MagNA Pure LC DNA
Isolation Kit I applying the manufacturers high perform-
ance protocol. Purified genomic DNA was eluted in 100
PL antiseptic water and stored at -20°C. Genotypes were
determined using sequence specific primers in a polymer-
ase chain reaction (SSP-PCR) [25]. A sequence specific
primer and a consensus primer produce a DNA product of
known size in this PCR. The sequence specific primer has
a mismatch at the 3' end which is designed to identify
each genotype variant. The PCR were carried out as
described in Ross et al. [26]. PCR products were then elec-
trophoresed on 1.5% agarose gels (Bioline Ltd, London,
UK) containing 0.14 mg/mL ethidium bromide (Sigma
Ltd, Poole, UK), at 200 volts/cm2 in 0.5% tris borate EDTA
buffer (Sigma Ltd, Poole, UK). Products were visualised
with a UV illuminator and photographed with a Polaroid
camera. The presence of an allele specific band of the
expected size, in conjunction with a control band was
used to identify an allele.
Construction of haplotypes
Genotype and allele frequencies and allele carriage were
calculated and checked for Hardy-Weinberg equilibrium.
Haplotypes were constructed from genotype information
from each patient using the computer program Phase
http://stephenslab.uchicago.edu/home.html[27,28].
Statistical analyses
The statistical software SPSS for windows v. 14.0 was used
to run non-parametric tests and to run a stepwise linear
regression analysis. Because the COMT alleles are
expected to be codominant with respect to the Rs4680
(Val158Met) polymorphism and COMT enzyme activity,
we used the Jonckheere-Terpstra test for comparison
between genotype groups, working with a hypothesis that
P1d P2d P3 (or the opposite P1t P2t P3) [29]. For all other
SNPs we used the Kruskal-Wallis test for comparison
between genotype groups. We used the logarithm (log10)
of the 24 hour morphine dose as the dependent variable
in the regression analyses because the 24 hour morphine
dose, as expected, did not display a normal distribution.
The analysis was a stepwise enter linear regression with a
criterion for removal of a variable of p > 0.1. The variables
included in the regression analysis as independent varia-
bles were: haplotype 1, age, gender, tumour diagnosis,
Karnofsky performance status, creatinine and albumin
serum concentration, time since diagnosis, time since
morphine treatment started, survival time after study, BPI
average pain score, EORTC score for fatigue, nausea and
vomiting, dyspnea, sleep, appetite and constipation, and
finally the sum score for the Mini mental examination
measuring cognitive function.
Interpretation of p values in this study is done with cau-
tion considering the multiplicity of tests carried out.
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Appendix 
 
 
I. Brief Pain Inventory 
II. EORTC QLQ-C30 
III. Minimental status (MMS) 
IV. Karnofsky Performance Scale 

Yes No
1. Throughout our lives, most of us have had pain from time to time (such as minor headaches,
      sprains, and toothaches). Have you had pain other than these everyday kinds of pain today?
2. On the diagram, shade in the areas where you feel pain. Put an X on the area that hurts the most.
3. Please rate your pain by circling the one number that best describes your pain at its worst in the last 24
      hours.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
4. Please rate your pain by circling the one number that best describes your pain at its least in the last 24
      hours.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
5. Please rate your pain by circling the one number that best describes your pain on the average.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
Please go to the next page
6. Please rate your pain by circling the one number that tells how much pain you have right now.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
Right RightLeft Left
CRF no:
NTNU         DMF, IKM
Brief Pain Inventory
New version
p. 1 of 2 Projectno.:
OPI 03-006
37414
7. In the last 24 hours, how much relief have pain treatments or medications provided? Please
      circle the one percentage that most shows how much relief you have recieved.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No Relief Complete Relief
Circle the one number that describes how, during the past 24 hours, pain has interfered with
your:
8. General Activity
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
9. Mood
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
10. Walking Ability
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
11. Normal work (includes both work outside the home and housework)
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
12. Relations with other people
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
13. Sleep
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
14. Enjoyment of  life
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
NTNU         DMF, IKM
Brief Pain Inventory
New version
p. 2 of 2 Projectno.:
OPI 03-006
CRF no:
37414
We are interested in some things about you and your health. Please answer all of these questions
yourself by ticking the alternative that best applies to you. There are no "right" or "wrong" answers. The
information that you provide will remain strictly confidential.
1. Do tou have any trouble doing strenuous activities,
like carrying a heavy shopping bag or a suitcase?
2. Do you have any trouble taking a long walk?
3. Do you have any trouble taking a short walk outside
of the house?
4. Do you need to stay in bed or a chair during the day?
5. Do you need help with eating, dressing, washing
yourself or using the toilet?
During the past week:
6. Were you limited in doing either your work or other
daily activities?
7. Were you limited in pursuing your hobbies or other
leisure time activities?
8. Were you short of breath?
9. Have you had pain?
10. Did you need to rest?
11. Have you had trouble sleeping?
12. Have you felt weak?
13. Have you lacked appetite?
14. Have you felt nauseated?
Not at
all
A
little
Quite
a bit
Very
much
Please go to the next page
CRF nr:
NTNU         DMF, IKM
EORTC QLQ-C30
(version 3)
p. 1 of 2 Projectno.:
OPI 03-006
Not at
all
A
little
Quite
a bit
Very
much
8476
For the following question please tick the number between 1 and 7 that best applies to you.
29. How would you rate your overall health during the past week?
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Versjon 3.0 1995©Copyright EORTC Study Group on Quality of Life. All rights reserved.
   During the past week:
1 2 3 4 5 6 7
Very poor Excellent
Very poor Excellent
15. Have you vomited?
16. Have you been constipated?
17. Have you had diarrhea?
18. Were you tired?
19. Did pain interfere with your daily activities?
20. Have you had difficulty in concentrating on things,
like reading a newspaper or watching TV?
21. Did you feel tense?
22. Did you worry?
23. Did you feel irritable?
24. Did you feel depressed?
25. Have you had difficulty remembering things?
26. Has your physical condition or medical treatment
interferred with your family life?
27. Has your physical condition or medical treatment 
interferred with your social activities?
28. Has your physical condition or medical treatment 
caused you financial difficulties?
NTNU         DMF, IKM
EORTC QLQ-C30
(version 3)
p. 2 of 2 Projectno.:
OPI 03-006
Not at
all
A
little
Quite
a bit
Very
much
CRF nr:
8476
What year is it?
What month is it?
What season is it?
What is today's date?
What day of the week is it?
What country are we in?
What province/state/county are we in?
What city/town are we in?
What is the name of this hospital? (What is your homeadress?)
What floor of the building are we on? (What is your postal code?)
1. ORIENTATION Score Maximum score
1
Name 3 objects:1 second to say each. BALL - CAR - MAN:Then ask
the patient all 3 after you have said them. Give 1 point for each correct
answer. Then repeat them until he learns all 3.
Count all trials
2. REGISTRATION
3. ATTENTION AND CALCULATION
Spell "world" backwards 1 point for each correct.
Alternatively: Ask patient to count backwards from 100 by sevens.
Stop after 5 answers.
4. RECALL
Ask for the the 3 objects repeated above?
Give 1 point for each correct. 
5. LANGUAGE
Name a pencil
Name a watch
Repeat the following "No ifs, ands or buts."
Follow a 3-stage command: Take a paper in your right hand,
fold it in half, and put it on the floor."
Read and obey the following: CLOSE YOUR EYES
Write a sentence
Copy design
TOTAL SCORE 30
1
1
1
1
1
1
1
1
1
3
5
3
1
1
1
1
1
1
3
CRF nr:
NTNU         DMF, IKM
Minimental status MMS
p. 1 of 4
Projectno.:
OPI 03-006
40306

CLOSE YOUR EYES
CRF nr:
NTNU         DMF, IKM
Minimental status MMS
p. 2 of 4
Projectno.:
OPI 03-006
Write a sentence
CRF nr:
NTNU         DMF, IKM
Minimental status MMS
p. 3 of 4
Projectno.:
OPI 03-006
Copy design
CRF nr:
NTNU         DMF, IKM
Minimental status MMS
p. 4 of 4
Projectno.:
OPI 03-006
Karnofsky Performance Scale 
Criteria for functional status for patient with malign disease 
100%
90%
80%
Normal, no complaints, no evidence of disease. 
Able to carry on normal activity: minor 
symptoms of disease. 
Normal activity with effort: some symptoms of 
disease.
70%
60%
50%
Cares for self: unable to carry on normal activity 
or active work. 
Requires occasional assistance but is able to 
care for needs. 
Requires considerable assistance and frequent 
medical care. 
40%
30%
20%
10%
Disabled: requires special care and assistance. 
Severely disabled: hospitalisation necessary: 
active treatment necessary. 
Very sick, hospitalisation necessary: active 
treatment necessary. 
Moribund, fatal processes progressing rapidly. 
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